Small molecule inhibitors of LAG-3
Small molecule inhibitors targeting LAG-3 by reducing its binding to MHC class II molecules provide an effective and tolerable treatment for cancer and infections, addressing the limitations of current immune checkpoint inhibitors by enhancing immune responses and improving treatment outcomes.
Patent Information
- Application Number
- PCT/GB2024/051441
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-02
- Filing Date
- 2024-06-03
- Publication Date
- 2024-12-05
AI Technical Summary
Current immune checkpoint inhibitors for cancer treatment, such as PD-1 and CTLA-4 blockers, have limitations including high costs, need for parental administration, and adverse events, prompting the search for alternative small molecule inhibitors that can effectively target LAG-3, a promising immune checkpoint, to enhance immune response against cancer and infections.
Development of small molecule inhibitors that specifically bind to LAG-3, reducing its interaction with MHC class II molecules, thereby blocking the inhibitory signal to T cells, which can be administered orally and potentially offer better tolerability and efficacy compared to monoclonal antibodies.
These small molecule inhibitors effectively block LAG-3-mediated inhibitory signals, enhancing immune responses against cancer cells and infectious agents, offering a cheaper, orally available, and potentially more effective treatment option with fewer adverse events compared to existing therapies.
Smart Images

Figure GB2024051441_05122024_PF_FP_ABST
Abstract
Description
[0001] Small molecule inhibitors of LAG-3 FIELD OF THE INVENTION This invention relates to small molecules that bind specifically to Lymphocyte-activation gene-3 (LAG-3), and to use of the small molecules as medicaments, in particular as LAG-3 inhibitors that inhibit the effects of LAG-3 on activated T-cells, for example for use in the treatment of cancer or infection. BACKGROUND OF THE INVENTION Immune checkpoint blockade (ICB) has revolutionised the treatment of cancer. Over the past decade, PD-1 and CTLA-4 immune checkpoint inhibitors such as OPDIVO (nivolumab), KEYTRUDA (pembrolizumab) and YERVOY (ipilimumab) have become the standard of care therapies for many forms of cancer, however unfortunately, many patients still fail to respond to these modern medicines. In an effort to improve patient outcomes, significant work has been undertaken to investigate other immune checkpoints, such as LAG-3, TIM-3, VISTA, CD47, IDO and TIGIT. LAG-3 in particular has emerged as a promising checkpoint and a number of companies are developing new inhibitors that target this checkpoint. Combining different ICB treatments can have greater efficacy than monotherapy. This was demonstrated in 2021 by the success of a clinical trial directed to the combined treatment of an anti-LAG-3 and anti-PD-1, improving progression free survival of patients with previously untreated metastatic or unresectable melanoma with a combination treatment of anti-LAG-3 and anti-PD-1 (10.1 months) compared to anti-PD1 alone (4.6 months) - see N. Engl. J. Med. 386, 24-35 (2022). However, combining different ICB treatments often comes with greater high grade treatment-induced adverse events. Another key finding of this anti-LAG-3 and anti-PD-1 trial was that grade 3 or 4 treatment related events were 18.9% for patients on dual therapy. This is substantially less than has been reported for patients treated with dual anti- CTLA-4 and anti-PD-1 (>50%), despite similar progression free survival - see N.Engl. J. Med. 369, 122-133 (2013). This suggests that dual treatment targeting LAG-3 instead of CTLA-4 is better tolerated, providing patients with a better quality of life without impacting upon progression free survival. Subsequent FDA approval of the therapeutic combination of anti-LAG-3 and anti-PD-1 (Opdualag) has thrust LAG-3 targeted therapies into the spotlight. The aim of a LAG-3 inhibitor, as with the currently approved PD-1 and CTLA-4 inhibitors, is to block the down-regulation of the immune system i.e. taking the “brakes off” the body’s immune processes. On T cells, LAG-3 is a co-inhibitory receptor physically associated with the T cell receptor and expressed on activated T cells and consequently, if LAG-3 is expressed on T cells, it has an inhibitory effect on activated T cells. When LAG-3 expressed on an activated CD8+ T cell binds to MHC class II at the same time as the T cell receptor (TCR) is binding to MHC class I on an APC, the LAG-3 binding stops calcium signaling which leads to a reduction in cytokine production and a decline in immune response. LAG-3 is a prime target for immune checkpoint blockade in immuno-oncology as it is readily expressed at high levels on tumor infiltrating lymphocytes in many human tumors. A LAG-3 inhibitor blocks the LAG-3-mediated inhibitory signal given to tumor infiltrating T cells. This allows the CD8+T cells to generate a better cytotoxic response against cancer cells. CD8+T cells also respond to viral infections, and participate in defence against bacterial, fungal and parasitic infections. Cytolytic effector CD8+T cells help to eliminate pathogens through cytokine secretion and direct killing of infected cells. A LAG-3 inhibitor blocks the LAG-3-mediated inhibitory signal given to CD8+T cells, which allows these cells to generate a better response against infectious agents. Most approved ICB therapies are monoclonal antibodies (mAb) which although successful, have disadvantages including their considerable cost, and need to be administered parenterally. Consequently, small molecule inhibitors (SMIs) are of increasing interest in immune-oncology, with efforts already underway to generate SMIs for PD-1:PD-L1 – see Scientific Reports, 12, 1-11 (2022). In contrast to mAbs, SMIs are considerably cheaper to produce, orally available and have short half-lives; allowing for greater flexibility with treatment strategy and potentially greater tumour penetration. Like the CD4 T cell co-receptor, LAG-3 consists of four extracellular immunoglobulin (Ig) domains (D1-D4). Both CD4 and LAG-3 have been shown to bind to MHC-II, with LAG-3 shown to bind with a far higher affinity. It has been reported that binding to MHC-II is dependent on a 30 amino acid (a.a) proline rich loop in domain 1 (D1), which is not present in CD4 – see Proc Natl Acad Sci USA, 94, 5744-5749 (1997). Thus, the applicants hypothesised that the interaction between LAG-3 and MHC-II may be a druggable target for a small molecule. SUMMARY OF THE INVENTION An object of the present invention is to provide compounds useful in treating disorders and diseases (e.g. a cancer or an infectious disease) wherein the treatment is affected or facilitated by the compound binding to human Lymphocyte Activation Gene-3 (LAG-3). The present invention relates to compounds that bind specifically to LAG-3 and reduce binding of LAG-3 to MHC class II molecules. In a most general first aspect the present invention provides a compound having the Formula (I): or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: Z is 0 or 1; n is 0 or 1; m is 0 or 1; Y is selected from an alkyl group or a heteroalkyl group, wherein the alkyl group or heteroalkyl group may be substituted or unsubstituted; A is selected from CH2, CHCH3or CO; B is selected from a secondary or tertiary amine containing group; wherein when B is a secondary amine containing group, X is selected from an alkyl group or a heteroalkyl group, wherein the alkyl group or heteroalkyl group may be substituted or unsubstituted; wherein when B is a tertiary amine containing group, B and X together form a heteroalkyl or heteroaryl ring group, wherein the heteroalkyl or heteroaryl ring group may be substituted or unsubstituted; or B is selected from NH2or OH when m=0 and Z=0; R is selected from an aryl group or a heteroaryl group, wherein the aryl group or heteroaryl group may be subsituted or unsubsituted; wherein the compound having the Formula (I) does not comprise a -COCH2O- functional group. The applicants have found that compounds comprising a central amine and / or amide group linked on either side to aromatic groups bind specifically to LAG-3 and therefore reduce binding of LAG-3 to MHC class II molecules. In a preferred embodiment, the present invention provides a compound having the Formula (I): or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: n is 0 or 1; m is 0 or 1; Y is selected from an alkyl group or a heteroalkyl group, wherein the alkyl group or heteroalkyl group may be substituted or unsubstituted; A is selected from CH2, CHCH3or CO; B is selected from a secondary or tertiary amine containing group; wherein when B is a secondary amine containing group, X is selected from an alkyl group or a heteroalkyl group, wherein the alkyl group or heteroalkyl group may be substituted or unsubstituted; wherein when B is a tertiary amine containing group, B and X together form a heteroalkyl or heteroaryl ring group, wherein the heteroalkyl or heteroaryl ring group may be substituted or unsubstituted; R is selected from an aryl group or a heteroaryl group, wherein the aryl group or heteroaryl group may be subsituted or unsubsituted; wherein the compound having the Formula (I) does not comprise a -COCH2O- linker group between the two R groups. Preferred compounds of the present invention are compounds as mentioned in the following list of structural formulae, as well as stereoisomeric forms and / or pharmaceutically acceptable salts thereof:
[0002]
[0003] Alternative representations of compounds 91-96 are shown in the table below. The above list of preferred compounds of the present invention may also be represented by the following IUPAC names: In a most general second aspect the present invention provides a compound having the Formula (II): or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: n is 0 or 1; X is selected from a primary amine, a secondary amine, a tertiary amine or a hydoxyl group. In a preferred embodiment, the present invention provides a compound having the Formula (II): or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: n is 0 or 1; X is selected from -OH, -NH2, -NHR1or -NR2R3; wherein R1is selected from an alkyl group or a heteroalkyl group which may optionally be substituted with an aryl group or a heteroaryl group, wherein the aryl group or heteroaryl group may be substituted or unsubstituted; wherein R2and R3are fused to form a heteroalkyl or heteroaryl ring group, wherein the heteroalkyl or heteroaryl ring group may be substituted or unsubstituted. In a preferred embodiment, the present invention provides a compound having the Formula (II): or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: n is 0 or 1; ; R1represents a group of the formula: wherein: m is 0, 1 or 2; Y is selected from N or CH; W is selected from -SO2NH2, -OCH3, -COOH, -NHCOCH3, -CN, -OH, -CH3or -N(CH3)2, -CH2SO2CH3, -NHCONH2, F, H, -NHSO2CH3, -CONH2, -SO2N(CH3)2, -CH2SO2NH2, -CONHCH3, or -CH2CN; or wherein R1represents a group of the formula: , ; wherein I is 0, 1 or 2; or wherein R1represents a group of the formula: , , B) . Preferred compounds of the present invention are compounds as mentioned in the following list of structural formulae, as well as stereoisomeric forms and / or pharmaceutically acceptable salts thereof:
[0004] The above list of preferred compounds of the present invention may also be represented by the following IUPAC names:
[0005] In a most general third aspect the present invention provides a compound having the Formula (III): or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: Z is 0 or 1; X is selected from CH3or H; A is selected from an alkyl group or a heteroalkyl group; R is selected from an aryl group, a heteroaryl group, an alkyl ring group or a heteroalkyl ring group, wherein the aryl group, heteroaryl group, alkyl ring group or heteroalkyl ring group may be subsituted or unsubsituted. In a preferred embodiment, the present invention provides a compound having the Formula (IV): or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: Z is 0 or 1; X is selected from CH3or H; A is selected from an alkyl group or a heteroalkyl group; Y is selected from CH or N; R1 and R2 and each independently selected from NO2, SO2CH3, OCH3, Cl, . Preferred compounds of the present invention are compounds as mentioned in the following list of structural formulae, as well as stereoisomeric forms and / or pharmaceutically acceptable salts thereof:
[0006] The above list of preferred compounds of the present invention may also be represented by the following IUPAC names:
[0007] In a most general fourth aspect the present invention provides a compound having the Formula (V): or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: wherein X is a tertiary amine ring group, wherein the tertiary amine ring group may be substituted or unsubstituted. In a preferred embodiment, the present invention provides a compound having the Formula (VI):
[0008] or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: Z is 0 or 1; Y is selected from SO2, an alkyl group or an alkyl ether group; R1 and R2 are each independently selected from NO2, OCH3, OCH2CH3or F. Preferred compounds of the present invention are compounds as mentioned in the following list of structural formulae, as well as stereoisomeric forms and / or pharmaceutically acceptable salts thereof:
[0009] The above list of preferred compounds of the present invention may also be represented by the following IUPAC names:
[0010] Preferred compounds of the present invention are compounds as mentioned in the following list of structural formulae, as well as stereoisomeric forms and / or pharmaceutically acceptable salts thereof:
[0011] The above list of preferred compounds of the present invention may also be represented by the following IUPAC names: Optionally compounds of the invention inhibit binding of LAG-3 to MHC class II molecules by at least 50%, for example as determined by AlphaScreen assay for blockade of LAG-3:Fc binding to HLA-DR1 at a compound concentration of 20 µM, as described below. The present invention also relates to a pharmaceutical composition comprising one or more compound(s) according to the present invention (e.g. compounds of Formula (I)). Preferably the pharmaceutical composition comprises a pharmaceutically acceptable carrier and / or excipient. The pharmaceutical compositions of the invention may be prepared by conventional methods in the art; the nature of the pharmaceutical composition employed will depend on the desired route of administration. Uses of Small Molecule Inhibitors of LAG-3 According to the invention there is provided a method of modulating an immune response in a subject. The method comprises administering to the subject a small molecule inhibitor of LAG-3 disclosed herein (e.g., a therapeutically effective amount of a small molecule inhibitor), alone or in combination with one or more agents or procedures, such that the immune response in the subject is modulated. Optionally, the small molecule inhibitor restores, enhances, stimulates or increases an immune response in the subject. According to the invention there is also provided a method of enhancing an immune response to an antigen in a subject, comprising administering to the subject: (i) the antigen; and (ii) a small molecule inhibitor of the invention, such that an immune response to the antigen in the subject is enhanced. The antigen can be, for example, a tumor antigen, a viral antigen, a bacterial antigen, or an antigen from a pathogen. The subject can be a mammal, e.g., a primate, preferably a higher primate, e.g., a human (e.g., a patient having, or at risk of having, a disorder described herein). In one embodiment, the subject is in need of enhancing an immune response. In some embodiments, the small molecule inhibitor restores, enhances or stimulates an antigen-specific T cell response, e.g., interleukin-2 (IL-2) or interferon-gamma (IFN-γ) production in an antigen-specific T cell response, in the subject. In some embodiments, the immune response is an anti-tumor response. In one embodiment, the subject has, or is at risk of, having a disorder described herein, e.g., a cancer or an infectious disorder as described herein. In certain embodiments, the subject is, or is at risk of being, immunocompromised. For example, the subject is undergoing or has undergone a chemotherapeutic treatment and / or radiation therapy. Alternatively, or in combination, the subject is, or is at risk of being, immunocompromised as a result of an infection. Cancer According to the invention there is provided a method of treating (e.g., one or more of reducing, inhibiting, or delaying progression of) a cancer or a tumor in a subject, which comprises administering to the subject a small molecule inhibitor of the invention (e.g., a therapeutically effective amount of a small molecule inhibitor of the invention). The small molecule inhibitor may be administered to the subject alone, e.g., as a monotherapy, or in combination, e.g., with one or more agents or procedures. In certain embodiments, the small molecule inhibitor is administered in combination with a modulator of a costimulatory molecule (e.g., an agonist of a costimulatory molecule) or a modulator of an inhibitory molecule (e.g., an inhibitor of an immune checkpoint), e.g., as described herein. In one embodiment, the small molecule inhibitor is administered in combination with an inhibitor or activator of an immune checkpoint (e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 modulator (e.g., a TIM-3 activator or inhibitor), a CEACAM (e.g., CEACAM1 and / or CEACAM5) inhibitor, or a CTLA-4 inhibitor. In certain embodiments, the cancer treated with the small molecule inhibitor, alone or in combination, includes but is not limited to, a solid tumor, a hematological cancer (e.g., leukemia, lymphoma, myeloma), and a metastatic lesion thereof. In one embodiment, the cancer is a solid tumor. Examples of solid tumors include malignancies, e.g., sarcomas and carcinomas (e.g., adenocarcinomas), of the various organ systems, such as those affecting lung, breast, lymphoid, gastrointestinal or colorectal, genitals and genitourinary tract (e.g., renal, urothelial, bladder cells), pharynx, CNS (e.g., brain, neural or glial cells), skin (e.g., melanoma), head and neck (e.g., head and neck squamous cell carcinoma (HNSCC)), and pancreas. For example, melanoma, colon cancers, gastric cancer, rectal cancer, renal-cell carcinoma, breast cancer (e.g., a breast cancer that does not express one, two or all of estrogen receptor, progesterone receptor, or Her2 / neu, e.g., a triple negative breast cancer), liver cancer, a lung cancer (e.g., a non-small cell lung cancer (NSCLC) (e.g., a NSCLC with squamous and / or non-squamous histology) or small cell lung cancer), prostate cancer, cancer of head or neck (e.g., HPV+squamous cell carcinoma), cancer of the small intestine and cancer of the oesophagus. Examples of hematological cancer include, but are not limited to, leukemia (e.g., a myeloid leukemia, lymphoid leukemia, or chronic lymphocytic leukemia (CLL)), lymphoma (e.g., Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), Diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma, or mantle cell lymphoma (VICL)), and myeloma, e.g., multiple myeloma. The cancer may be at an early, intermediate, late stage or metastatic cancer. In some embodiments, the cancer is chosen from a colorectal cancer (e.g., CRC), melanoma, e.g., advanced stage melanoma (e.g., stage II-IV melanoma) or HLA-A2 positive-melanoma; a pancreatic cancer, e.g., advanced pancreatic cancer; a breast cancer, e.g., metastatic breast carcinoma or triple negative breast cancer; a head and neck cancer (e.g., HNSCC); an esophageal cancer; a renal cell carcinoma (RCC), e.g., clear renal cell carcinoma (ccRCC) or metastatic renal cell carcinoma (MRCC); a lung cancer (e.g., NSCLC); a cervical cancer; bladder cancer; or a hematologic malignancy, e.g., a leukemia (e.g., a lymphocytic leukemia), or a lymphoma (e.g., a Hogdkin's lymphoma (HL), a non-Hogdkin's lymphoma (NHL), a diffuse large B-cell lymphoma (DLBCL), a mantle cell lymphoma (MCL), or a CLL, e.g., a relapsed or refractory chronic lymphocytic leukemia). Methods and compositions disclosed herein are useful for treating metastatic lesions associated with the aforementioned cancers. Infectious Disease According to the invention there is also provided a method of treating (e.g., one or more of reducing, inhibiting, or delaying progression of) an infectious disease in a subject, which comprises administering to the subject a small molecule inhibitor of the invention (e.g., a therapeutically effective amount of a small molecule inhibitor of the invention). The small molecule inhibitor may be administered to the subject alone, e.g., as a monotherapy, or in combination, e.g., with one or more agents or procedures. In the treatment of infection (e.g., acute and / or chronic), administration of a small molecule inhibitor of the invention (alone or in combination with an immune checkpoint modulator (e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 modulator (e.g., a TIM-3 activator or inhibitor), a CEACAM (e.g., CEACAM1 and / or CEACAM5) inhibitor, or a CTLA-4 inhibitor) can be combined with conventional treatments in addition to or in lieu of stimulating natural host immune defenses to infection. Natural host immune defenses to infection include, but are not limited to inflammation, fever, antibody-mediated host defense, T-lymphocyte-mediated host defenses, including lymphokine secretion and cytotoxic T-cells (especially during viral infection), complement mediated lysis and opsonization (facilitated phagocytosis), and phagocytosis. The ability of the small molecule inhibitors of the invention to reactivate dysfunctional T-cells would be useful to treat chronic infections, in particular those in which cell-mediated immunity is important for complete recovery. Small molecule mediated LAG-3 blockade can be used alone, or as an adjuvant, in combination with vaccines, to stimulate the immune response to pathogens, toxins, and self- antigens. Examples of pathogens for which this therapeutic approach may be particularly useful, include pathogens for which there is currently no effective vaccine, or pathogens for which conventional vaccines are less than completely effective. These include, but are not limited to Hepatitis (A, B, and C), Influenza, HIV, Herpes, Giardia, Malaria, Leishmania, Staphylococcus aureus, Pseudomonas Aeruginosa. LAG-3 blockade is particularly useful against established infections by agents such as HIV that present altered antigens over the course of the infections. These novel epitopes are recognized as foreign at the time of small molecule inhibitor administration, thus provoking a strong T cell response that is not dampened by negative signals through LAG-3. Viruses For infections resulting from viral causes, a small molecule inhibitor of the invention (alone or in combination with an immune checkpoint modulator (e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 modulator (e.g., a TIM-3 activator or inhibitor), a CEACAM (e.g., CEACAM1 and / or CEACAM5) inhibitor, or a CTLA-4 inhibitor) can be combined by application simultaneous with, prior to or subsequent to application of standard therapies for treating viral infections. Such standard therapies vary depending on the type of virus, although in almost all cases, administration of human serum containing antibodies (e.g., IgA, IgG) specific to the virus can be effective. Some examples of pathogenic viruses causing infections treatable by methods of the invention include hepatitis (A, B, or C), influenza virus (A, B, or C), HIV, herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, CMV, Epstein Barr virus), adenovirus, flaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus. In one embodiment, the infection is an influenza infection. Influenza infection can result in fever, cough, myalgia, headache and malaise, which often occur in seasonal epidemics. Influenza is also associated with a number of postinfectious disorders, such as encephalitis, myopericarditis, Goodpasture's syndrome, and Reye's syndrome. Influenza infection also suppresses normal pulmonary antibacterial defenses, such that patient's recovering from influenza have an increased risk of developing bacterial pneumonia. Influenza viral surface proteins show marked antigenic variation, resulting from mutation and recombination. Thus, cytolytic T lymphocytes are the host's primary vehicle for the elimination of virus after infection. Influenza is classified into three primary types: A, B and C. Influenza A is unique in that it infects both humans and many other animals (e.g., pigs, horses, birds and seals) and is the principal cause of pandemic influenza. Also, when a cell is infected by two different influenza A strains, the segmented RNA genomes of two parental virus types mix during replication to create a hybrid replicant, resulting in new epidemic strains. Influenza B does not replicate in animals and thus has less genetic variation and influenza C has only a single serotype. Most conventional therapies are palliatives of the symptoms resulting from infection, while the host's immune response actually clears the disease. However, certain strains (e.g., influenza A) can cause more serious illness and death. Influenza A may be treated both clinically and prophylactically by the administration of the cyclic amines inhibitors amantadine and rimantadine, which inhibit viral replication. However, the clinical utility of these drugs is limited due to the relatively high incidence of adverse reactions, their narrow anti-viral spectrum (influenza A only), and the propensity of the virus to become resistant. The administration of serum IgG antibody to the major influenza surface proteins, hemagglutinin and neuraminidase can prevent pulmonary infection, whereas mucosal IgA is required to prevent infection of the upper respiratory tract and trachea. The most effective current treatment for influenza is vaccination with the administration of virus inactivated with formalin or P-propiolactone. In one embodiment, a small molecule inhibitor of the invention is administered in combination with an influenza antigen or vaccine. In another embodiment, the infection is a hepatitis infection, e.g., a Hepatitis B or C infection. Hepatitis B virus (HBV) is the most infectious known bloodborne pathogen. It is a major cause of acute and chronic heptatitis and hepatic carcinoma, as well as life-long, chronic infection. Following infection, the virus replicates in hepatocytes, which also then shed the surface antigen HBsAg. The detection of excessive levels of HBsAg in serum is used a standard method for diagnosing a hepatitis B infection. An acute infection may resolve or it can develop into a chronic persistent infection. Current treatments for chronic HBV include a-interferon, which increases the expression of class I human leukocyte antigen (HLA) on the surface of hepatocytes, thereby facilitating their recognition by cytotoxic T lymphocytes. Additionally, the nucleoside analogs ganciclovir, famciclovir and lamivudine have also shown some efficacy in the treatment of HBV infection in clinical trials. Additional treatments for HBV include pegylated a-interferon, adenfovir, entecavir and telbivudine. While passive immunity can be conferred through parental administration of anti-HBsAg serum antibodies, vaccination with inactivated or recombinant HBsAg also confers resistance to infection. A small molecule inhibitor of the invention (alone or in combination with an immune checkpoint modulator (e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 modulator (e.g., a TIM-3 activator or inhibitor), a CEACAM (e.g., CEACAM1 and / or CEACAM5) inhibitor, or a CTLA-4 inhibitor)) may be combined with conventional treatments for hepatitis B infections for therapeutic advantage. In one embodiment, the small molecule inhibitor is administered in combination with a hepatitis B antigen or vaccine, and optionally in combination with an aluminum- containing adjuvant. Hepatitis C virus (HCV) infection may lead to a chronic form of hepatitis, resulting in cirrosis. While symptoms are similar to infections resulting from Hepatitis B, in distinct contrast to HBV, infected hosts can be asymptomatic for 10-20 years. The small molecule inhibito can be administered as a monotherapy (or in combination with an immune checkpoint modulator (e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 modulator (e.g., a TIM-3 activator or inhibitor), a CEACAM (e.g., CEACAM1 and / or CEACAM5) inhibitor, or a CTLA-4 inhibitor)), or all of the foregoing can be combined with the standard of care for hepatitis C infection. Conventional treatment for HC-V infection includes the administration of a combination of α- interferon and ribavirin. A promising potential therapy for HC-V infection is the protease inhibitor telaprevir (VX-960). Additional treatments include: anti-PD-1 antibody (e.g., MDX- 1106, Medarex), bavituximab (an antibody that binds anionic phospholipid phosphatidylserine in a B2-glycoprotein I dependent manner, Peregrine Pharmaceuticals), anti-HPV viral coat protein E2 antibod(y)(ies) (e.g., ATL 6865—Ab68+Ab65, XTL Pharmaceuticals) and Civacir® (polyclonal anti-HCV human immune globulin). A small molecule inhibitor of the invention may be combined with one or more of these treatments for hepatitis C infections for therapeutic advantage. In another embodiment, the infection is a measles virus. After an incubation of 9-11 days, hosts infected with the measles virus develop fever, cough, coryza and conjunctivitis. Within 1-2 days, an erythematous, maculopapular rash develop, which quickly spreads over the entire body. Because infection also suppresses cellular immunity, the host is at greater risk for developing bacterial superinfections, including otitis media, pneumonia and postinfectious encephalomyelitis. Acute infection is associated with significant morbidity and mortality, especially in malnourished adolescents. Treatment for measles includes the passive administration of pooled human IgG, which can prevent infection in non-immune subjects, even if given up to one week after exposure. However, prior immunization with live, attenuated virus is the most effective treatment and prevents disease in more than 95% of those immunized. As there is one serotype of this virus, a single immunization or infection typically results in protection for life from subsequent infection. In a small proportion of infected hosts, measles can develop into SSPE, which is a chronic progressive neurologic disorder resulting from a persistent infection of the central nervous system. SSPE is caused by clonal variants of measles virus with defects that interfere with virion assembly and budding. For these patients, reactivation of T-cells with a small molecule inhibitor of the invention so as to facilitate viral clearance would be desirable. In another embodiment, the infection is HIV. HIV attacks CD4+ cells, including T- lymphocytes, monocyte-macrophages, follicular dendritic cells and Langerhan's cells, and CD4+ helper / inducer cells are depleted. As a result, the host acquires a severe defect in cell- mediated immunity. Infection with HIV results in AIDS in at least 50% of individuals, and is transmitted via sexual contact, administration of infected blood or blood products, artificial insemination with infected semen, exposure to blood-containing needles or syringes and transmission from an infected mother to infant during childbirth. A host infected with HIV may be asymptomatic, or may develop an acute illness that resembling mononucleosis-fever, headache, sore throat, malaise and rash. Symptoms can progress to progressive immune dysfunction, including persistent fever, night sweats, weight loss, unexplained diarrhea, eczema, psoriasis, seborrheic dermatitis, herpes zoster, oral candidiasis and oral hairy leukoplakia. Opportunistic infections by a host of parasites are common in patients whose infections develop into AIDS. Treatments for HIV include antiviral therapies including nucleoside analogs, zidovudine (AST) either alone or in combination with didanosine or zalcitabine, dideoxyinosine, dideoxycytidine, lamidvudine, stavudine; reverse transcriptive inhibitors such as delavirdine, nevirapine, loviride, and proteinase inhibitors such as saquinavir, ritonavir, indinavir and nelfinavir. A small molecule inhibitor of the invention (alone or in combination with an immune checkpoint modulator (e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 modulator (e.g., a TIM-3 activator or inhibitor), a CEACAM (e.g., CEACAM1 and / or CEACAM5) inhibitor, or a CTLA-4 inhibitor) may be combined with conventional treatments for HIV infections for therapeutic advantage. In another embodiment, the infection is a Cytomegalovirus (CMV). CMV infection is often associated with persistent, latent and recurrent infection. CMV infects and remains latent in monocytes and granulocyte-monocyte progenitor cells. The clinical symptoms of CMV include mononucleosis-like symptoms (i.e., fever, swollen glands, malaise), and a tendancy to develop allergic skin rashes to antibiotics. The virus is spread by direct contact. The virus is shed in the urine, saliva, semen and to a lesser extent in other body fluids. Transmission can also occur from an infected mother to her fetus or newborn and by blood transfusion and organ transplants. CMV infection results in general impairment of cellular immunity, characterized by impaired blastogenic responses to nonspecific mitogens and specific CMV antigens, diminished cytotoxic ability and elevation of CD8 lymphocyte number of CD4+ lymphocytes. Treatments of CMV infection include the anti-virals ganciclovir, foscarnet and cidovir, but these drugs are typically only prescribed in immunocompromised patients. A small molecule inhibitor of the invention (alone or in combination with an immune checkpoint modulator (e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 modulator (e.g., a TIM-3 activator or inhibitor), a CEACAM (e.g., CEACAM1 and / or CEACAM5) inhibitor, or a CTLA-4 inhibitor) may be combined with conventional treatments for cytomegalovirus infections for therapeutic advantage. In another embodiment, the infection is Epstein-Barr virus (EBV). EBV can establish persistent and latent infections and primarily attacks B cells. Infection with EBV results in the clinical condition of infectious mononucleosis, which includes fever, sore throat, often with exudate, generalized lymphadenopathy and splenomegaly. Hepatitis is also present, which can develop into jaundice. While typical treatments for EBV infections are palliative of symptoms, EBV is associated with the development of certain cancers such as Burkitt's lymphoma and nasopharyngeal cancer. Thus, clearance of viral infection before these complications result would be of great benefit. A small molecule inhibitor of the invention (alone or in combination with an immune checkpoint modulator (e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 modulator (e.g., a TIM-3 activator or inhibitor), a CEACAM (e.g., CEACAM1 and / or CEACAM5) inhibitor, or a CTLA-4 inhibitor) may be combined with conventional treatments for Epstein-Barr virus infections for therapeutic advantage. In another embodiment, the infection is Herpes simplex virus (HSV). HSV is transmitted by direct contact with an infected host. A direct infection may be asymptomatic, but typically result in blisters containing infectious particles. The disease manifests as cycles of active periods of disease, in which lesions appear and disappear as the viral latently infect the nerve ganglion for subsequent outbreaks. Lesions may be on the face, genitals, eyes and / or hands. In some case, an infection can also cause encephalitis. Treatments for herpes infections are directed primarily to resolving the symptomatic outbreaks, and include systemic antiviral medicines such as: acyclovir (e.g., Zovirax®), valaciclovir, famciclovir, penciclovir, and topical medications such as docosanol (Abreva®), tromantadine and zilactin. The clearance of latent infections of herpes would be of great clinical benefit. A small molecule inhibitor of the invention (alone or in combination with an immune checkpoint modulator (e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 modulator (e.g., a TIM-3 activator or inhibitor), a CEACAM (e.g., CEACAM1 and / or CEACAM5) inhibitor, or a CTLA-4 inhibitor) may be combined with conventional treatments for herpes virus infections for therapeutic advantage. In another embodiment, the infection is Human T-lymphotrophic virus (HTLV-1, HTLV-2). HTLV is transmitted via sexual contact, breast feeding or exposure to contaminated blood. The virus activates a subset of TH cells called Thl cells, resulting in their overproliferation and overproduction of Thl related cytokines (e.g., IFN-y and TNF-a). This in turn results in a suppression of Th2 lymphocytes and reduction of Th2 cytokine production (e.g., IL-4, IL-5, IL-10 and IL-13), causing a reduction in the ability of an infected host to mount an adequate immune response to invading organisms requiring a Th2-dependent response for clearance (e.g., parasitic infections, production of mucosal and humoral antibodies). HTLV infections cause lead to opportunistic infections resulting in bronchiectasis, dermatitis and superinfections with Staphylococcus spp. and Strongyloides spp. resulting in death from polymicrobial sepsis. HTLV infection can also lead directly to adult T-cell leukemia / lymphoma and progressive demyelinating upper motor neuron disease known as HAM / TSP. The clearance of HTLV latent infections would be of great clinical benefit. A small molecule inhibitor of the invention (alone or in combination with an immune checkpoint modulator (e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 modulator (e.g., a TIM-3 activator or inhibitor), a CEACAM (e.g., CEACAM1 and / or CEACAM5) inhibitor, or a CTLA-4 inhibitor) may be combined with conventional treatments for HTLV infections for therapeutic advantage. In another embodiment, the infection is Human papilloma virus (HPV). HPV primarily affects keratinocytes and occurs in two forms: cutaneous and genital. Transmission it believed to occur through direct contact and / or sexual activity. Both cutaneous and genital HPV infection, can result in warts and latent infections and sometimes recurring infections, which are controlled by host immunity which controls the symptoms and blocks the appearance of warts, but leaves the host capable of transmitting the infection to others. Infection with HPV can also lead to certain cancers, such as cervical, anal, vulvar, penile and oropharynial cancer. There are no known cures for HPV infection, but current treatment is topical application of Imiquimod, which stimulates the immune system to attack the affected area. The clearance of HPV latent infections would be of great clinical benefit. A small molecule inhibitor of the invention (alone or in combination with an immune checkpoint modulator (e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 modulator (e.g., a TIM-3 activator or inhibitor), a CEACAM (e.g., CEACAM1 and / or CEACAM5) inhibitor, or a CTLA-4 inhibitor) may be combined with conventional treatments for HPV infections for therapeutic advantage. Bacterial Infections Some examples of pathogenic bacteria causing infections treatable by methods of the invention include syphilis, chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme disease bacteria (Borrelia species). A small molecule inhibitor of the invention (alone or in combination with an immune checkpoint modulator (e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 modulator (e.g., a TIM-3 activator or inhibitor), a CEACAM (e.g., CEACAM1 and / or CEACAM5) inhibitor, or a CTLA-4 inhibitor) can be used in combination with existing treatment modalities for the aforesaid infections. Fungi and Parasites Some examples of pathogenic fungi causing infections treatable by methods of the invention include Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum. Some examples of pathogenic parasites causing infections treatable by methods of the invention include Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis. Administration of small molecule inhibitors of the invention A small molecule inhibitor, alone or in combination, can be administered to the subject systemically (e.g., orally, parenterally, subcutaneously, intravenously, rectally, intramuscularly, intraperitoneally, intranasally, transdermally, or by inhalation or intracavitary installation), topically, or by application to mucous membranes, such as the nose, throat and bronchial tubes. Dosages and therapeutic regimens of the small molecule inhibitor can be determined by a skilled artisan. In certain embodiments, the small molecule inhibitor is administered orally at a dose of about 0.01 mg to 1000 mg, e.g.0.1 mg to 100 mg, e.g.1 mg to 10 mg. The dosing schedule can vary from e.g., once a week to once every 2, 3, or 4 weeks. In one embodiment, the small molecule inhibitor is administered at a dose from about 0.1 mg to 100 mg every other week. In one embodiment, the small molecule inhibitor is administered (e.g., orally) at a dose from about 1mg to 10 mg. In certain embodiments, the small molecule inhibitor is administered alone at a dose from about 0.01 mg to 1000 mg, e.g.0.1 mg to 100 mg, e.g.1 mg to 10 mg. In other embodiments, the small molecule inhibitor is administered at a dose from about 0.01 mg to 1000 mg, e.g. 0.1 mg to 100 mg, e.g. 1 mg to 10 mg, when it is combined with a second agent or therapeutic modality, e.g., a second agent or therapeutic modality described herein. In one embodiment, the small molecule inhibitor is administered every 2 weeks (e.g., during weeks 1, 3, 5, 7) during each 8 week cycle, e.g., up to 96 weeks. Medical Use and Methods of Treatment The compounds according to the present invention (e.g. compounds of Formula (I)) may be for use as a medicament. The compounds according to the present invention (e.g. compounds of Formula (I)) are capable of binding to human Lymphocyte Activation Gene-3 (LAG-3). In particular, compounds of the present invention are capable of binding to dimeric LAG-3 and monomeric LAG-3. Further, the compounds according to the present invention (e.g. compounds of Formula (I)) are capable of reducing binding of LAG-3 to a major histocompatibility (MHC) class II molecule. In particular, the compounds according to the present invention (e.g. compounds of Formula (I)) are capable of reducing binding of LAG-3 to human leukocyte antigen (HLA)- II. In particular, the compounds according to the present invention (e.g. compounds of Formula (I)) are capable of reducing binding of LAG-3 to HLA-DR1, HLA-DR4 and / or HLA- DQ8. Further, compounds of the present invention (e.g. compounds of Formula (I)) are capable of reducing binding of LAG-3 to FGL-1. By inhibiting the binding of LAG-3 to MHC-II, the compounds according to the present invention (e.g. compounds of Formula (I)) are capable of blocking the LAG-3-mediated inhibitory signal given to tumor infiltrating T cells (or effector CD8+T cells). Therefore, the compounds according to the present invention (e.g. compounds of Formula (I)) are capable of enhancing an immune response (e.g. a T cell response, such as an antigen-specific T cell response) in a subject. The compounds according to the present invention (e.g. compounds of Formula (I)) may be used in the prevention, treatment or amelioration of a cancer in a subject. The compounds according to the present invention (e.g. compounds of Formula (I)) may be used in the prevention, treatment or amelioration of an infectious disease in a subject. BRIEF DESCRIPTION OF THE FIGURES Figure 1 shows data from a LAG-3 vs HLA-II small molecule library screen. A) AlphaScreenTMcross titration of LAG-3:Fc (0.3 to 3 nM) and HLA-DR1 (0.3 to 30 nM). Data are representative of a minimum of three independent experiments. B) Flow diagram to demonstrate small molecule library screen design. C) Heat map illustrating percentage blockade of compound pools screened; low (blue), to high (yellow) data singlicate reading. D) Heat map of active wells identified in C) screened using a TruHit assay; yellow active wells turned blue if compounds demonstrated greater than 20% signal inhibition compared to DMSO only, data singlicate reading. E) As D) screened against TCR / pHLA-A2 an interaction with a similar affinity to that predicted for LAG-3:Fc for HLA-DR1 interaction between PPI, singlicate reading. F) Heat map of deconvolution of active wells, low (blue) to high (red) percentage blockade. First column shows percentage blockade of compound pool (active well) and each subsequent column shows each of compound from the pool individually, data average of duplicate readings. In Figure 1A, the lines in order from the top to the bottom of the “HLA-DR1” graph are as follows: 30 nM, 10 nM, 3 nM, 1 nM, and 0.3 nM. The lines in order from the top to the bottom of the “LAG-3:Fc” graph are as follows: 3 nM, 1 nM, and 0.3 nM. Figure 2A shows compounds 91, 25, 81, 79, 27, 78, 77 and 74 according to the present invention were serial diluted and screened using AlphaScreen. The data is representative of a minimum of three independent experiments. Figure 2B shows compounds 25 and 27 according to the present invention were serial diluted and screened using AlphaScreen. The data is representative of a minimum of three independent experiments. Figure 2C shows compound 81 according to the present invention was serial diluted and screened using AlphaScreen. The data is representative of a minimum of three independent experiments. Figure 2D shows compounds 78, 77 and 74 according to the present invention were serial diluted and screened using AlphaScreen. The data is representative of a minimum of three independent experiments. Figure 3A shows the AlphaScreen cross titration of LAG-3his and HLA-DR1 using streptavidin donor beads and nickel chelate acceptor beads, n=1. B) Compounds 91, 81, 79, 78, 77 and 74 block LAG-3 monomers from binding to HLA-DR1, data average of 2 duplicates. C) Compound 81 blocks LAG-3 monomers from binding to HLA-DR1, data average of 2 duplicates. D) Compounds 78, 77 and 74 block LAG-3 monomers from binding to HLA-DR1, data average of 2 duplicates. Figure 4 shows that LAG-3:HLA II blockade is not restricted to HLA-DR1. AlphaScreen compound dose response assays demonstrated small molecule compounds 91, 81, 79, 78, 77 and 74 block LAG-3:Fc binding to A) HLA-DR1, B) -DR4 and C) -DQ8 with IC50s (µM) calculated from dose response curves in D). AlphaScreen compound dose response assays demonstrated small molecule compound 81 blocks LAG-3:Fc binding to E) HLA-DR1, F) -DR4 and G) -DQ8 with IC50s (µM) calculated from dose response curves in H). AlphaScreen compound dose response assays demonstrated small molecule compounds 78, 77 and 74 block LAG-3:Fc binding to I) HLA-DR1, J) -DR4 and K) -DQ8 with IC50s (µM) calculated from dose response curves in L). Figure 5A shows the AlphaScreen FGL1:LAG-3:Fc cross titration, average of two independent experiments error bars = SD. Figure 5B shows compounds 91, 81, 79, 78, 77 and 74, 25 and 27 according to the present invention (10 µM) inhibited binding of 100% of LAG-3:Fc to HLA-DR1 and did not non- specifically inhibit anti-DR antibody L243 binding to HLA-DR1 but did interfere with binding of LAG-3 to FGL1. Data representative of a minimum of 2 independent experiments. Figure 5C shows the AlphaScreen FGL1:LAG-3:Fc cross titration, average of two independent experiments error bars = SD. Figure 5D shows compounds 25 and 27 according to the present invention (10 µM) inhibited binding of 100% of LAG-3:Fc to HLA-DR1 and did not non-specifically inhibit anti-DR antibody L243 binding to HLA-DR1 but did interfere with binding of LAG-3 to FGL1. Data representative of a minimum of 2 independent experiments. Figure 5E shows the AlphaScreen FGL1:LAG-3:Fc cross titration, average of two independent experiments error bars = SD. Figure 5F shows compound 81 according to the present invention (10 µM) inhibited binding of 100% of LAG-3:Fc to HLA-DR1 and did not non-specifically inhibit anti-DR antibody L243 binding to HLA-DR1 but did interfere with binding of LAG-3 to FGL1. Data representative of a minimum of 2 independent experiments. Figure 5G shows the AlphaScreen FGL1:LAG-3:Fc cross titration, average of two independent experiments error bars = SD. Figure 5H shows compounds 78, 77 and 74 according to the present invention (10 µM) inhibited binding of 100% of LAG-3:Fc to HLA-DR1 and did not non-specifically inhibit anti- DR antibody L243 binding to HLA-DR1 but did interfere with binding of LAG-3 to FGL1. Data representative of a minimum of 2 independent experiments. Figure 6A shows compounds 81, 79, 78, 77 and 74 inhibit soluble LAG-3:Fc from binding to MHC-II at the cell surface. Inhibition of LAG-3:Fc induced CCL4 production by THP-1 cells when treated with serially diluted compounds. Percentage inhibition calculated from CCL4 secreted by DMSO only treated cells. Data are representative of a minimum of two independent experiments. Figure 6B shows CCL4 pg / mL production by THP-1 cells treated with compounds 25, 81, 79, 27, 78, 77 and 74 according to the present invention. Figure 6C shows the corresponding percentage inhibition of CCL4 production. Percentage inhibition calculated from CCL4 secreted by DMSO only treated cells. Data are representative of a minimum of two independent experiments. Figure 6D shows CCL4 pg / mL production by THP-1 cells treated with compounds 25 and 27 according to the present invention. Figure 6E shows the corresponding percentage inhibition of CCL4 production. Percentage inhibition calculated from CCL4 secreted by DMSO only treated cells. Data are representative of a minimum of two independent experiments. Figure 6F shows compound 81 inhibits soluble LAG-3:Fc from binding to MHC-II at the cell surface. Inhibition of LAG-3:Fc induced CCL4 production by THP-1 cells when treated with serially diluted compounds. Percentage inhibition calculated from CCL4 secreted by DMSO only treated cells. Data are representative of a minimum of two independent experiments. Figure 6G shows CCL4 pg / mL production by THP-1 cells treated with compound 81 according to the present invention. Figure 6H shows the corresponding percentage inhibition of CCL4 production. Percentage inhibition calculated from CCL4 secreted by DMSO only treated cells. Data are representative of a minimum of two independent experiments. Figure 6I shows compounds 78, 77 and 74 inhibit soluble LAG-3:Fc from binding to MHC-II at the cell surface. Inhibition of LAG-3:Fc induced CCL4 production by THP-1 cells when treated with serially diluted compounds. Percentage inhibition calculated from CCL4 secreted by DMSO only treated cells. Data are representative of a minimum of two independent experiments. Figure 6J shows CCL4 pg / mL production by THP-1 cells treated with compounds 78, 77 and 74 according to the present invention. Figure 6K shows the corresponding percentage inhibition of CCL4 production. Percentage inhibition calculated from CCL4 secreted by DMSO only treated cells. Data are representative of a minimum of two independent experiments. Figure 7 shows data from a screen of the Screen 1 hit analogues. A) the top analogues were serial diluted and screened. Data average of three independent experiments. B) structure of the top 6 compounds from the analogue screen. Figure 7 shows data from a screen of the Screen 1 hit analogues. C) the top analogues were serial diluted and screened. Data average of three independent experiments. D) structure of the top 4 compounds from the analogue screen. Figure 7 shows data from a screen of the Screen 1 hit analogues. E) the top analogue was serial diluted and screened. Data average of three independent experiments. Figure 7F shows hit compound 80 with chemical scaffold identified by HTVS. Figure 7G shows data from a screen of compound 51. Data average of three independent experiments. Figure 7H shows hit compound 51 with chemical scaffold identified by HTVS. Figure 8 shows the Enamine small molecule library screen identifies novel LAG-3:HLA-II blockers. A) Heat map representing inhibition of the LAG-3:Fc:HLA-DR1 interaction by pooled compounds, (five per well at a final concentration of 5 µM), compounds screened via AlphaScreen, n=1. B) Bar graph grouping compound pools, percentage signal inhibition of the LAG-3-HLA-DR1 interaction from 0% to 100%. Percentage αsignal inhibition of compound pools in each screen plate was determined using the average αsignal of wells treated with DMSO only. C) Heatmap showing αsignal inhibition of the LAG-3-HLA-DR1 interaction for each compound (5 µM). Compounds are grouped (columns) by the pool in which they were screened and the combined inhibition of each pools is also shown in the top row. Grey indicates compounds selected but not delivered by Enamine due to quality control issues (grey is at the folowing positions: row 1, column 13; row 4, column 5; and row 5, column 33). Data is representative of 5 technical repeats from two independent experiments D) Scatter plot further demonstrating αsignal inhibition by compounds. Colour identifies compounds from the same pool. The grey “S-Z” zone illustrates the range of signal inhibition achieved by the original 8 compounds, to facilitate identification and rank of novel hits. E) Bar chart to demonstrate percentage αsignal inhibition of LAG-3-HLA-DR1 by the most potent compounds identified during deconvolution, where grey portion indicates αsignal inhibition independent of protein-protein interaction, as determined by a TruHit assay. Percentage αsignal inhibition was determined using the average αsignal of wells treated with DMSO only. Data is a representative of a minimum of 2 technical repeats. F) Using the same individual compound stock solutions provided by Enamine (from which the compounds were originally deconvoluted), a 10-point 1 in 2 dilution series of top seven most potent and specific each compounds (starting at 20 µM), was prepared and screened against the LAG-3-HLA- DR1 interaction via AlphaScreen. Percentage αsignal inhibition of the compounds was determined using the average αsignal of wells treated with DMSO only. The structures and IC50 values of each compound are also displayed. Data points are the average inhibition from three repeat experiments, error bars = SD. G) Bar chart to demonstrate percentage αsignal inhibition of LAG-3-HLA-DR1 by the most potent compounds identified during deconvolution, where grey portion indicates αsignal inhibition independent of protein-protein interaction, as determined by a TruHit assay. Percentage αsignal inhibition was determined using the average αsignal of wells treated with DMSO only. Data is a representative of a minimum of 2 technical repeats. H) Using the same individual compound stock solutions provided by Enamine (from which the compounds were originally deconvoluted), a 10-point 1 in 2 dilution series of top seven most potent and specific each compounds (starting at 20 µM), was prepared and screened against the LAG-3-HLA- DR1 interaction via AlphaScreen. Percentage αsignal inhibition of the compounds was determined using the average αsignal of wells treated with DMSO only. The structures and IC50 values of each compound are also displayed. Data points are the average inhibition from three repeat experiments, error bars = SD. Figure 9 shows validation of library screen hits identifies active compounds. A) Overlayed dose response curves (calculated using percentage αsignal inhibition of DMSO only LAG-3- HLA-DR1) of the top seven compounds 68, 93, 70, 92, 75, 94 and 69. Data points are the average inhibition from a single experiment performed in triplicate, error bars = SD. B) A table comparing the IC50 values from DMSO compound solutions prepared by Enamine and DMSO solutions prepared from powders (provided by Enamine) in Cardiff. C) Bar charts show the percentage αsignal inhibition of compounds at 0.1, 1 and 10 µM, for three separate protein-protein interactions: LAG-3-HLA-DR1 (“DR1 vs LAG-3”), HLA-A2-TCR (“A2 vs TCR”) and L243-HLA-DR1 (“DR1 vs L243”). Percentage αsignal inhibition was determined using the average αsignal of wells treated with DMSO only. Data is a representative of a minimum of 2 assay repeats. Figure 9 D) inhibition of LAG-3:Fc induced CCL4 production by THP-1 cells when treated with serially diluted compounds (5µM 1 in 2 dilution series). CCL4 pg / mL by THP-1 cells treated with hit compounds 68, 92, 70, 75, 93 and 94, E) corresponding percentage inhibition of CCL4 production. F) Overlayed dose response curves (calculated using percentage αsignal inhibition of DMSO only LAG-3-HLA-DR1) of the top seven compounds 68, 70, 75, and 69. Data points are the average inhibition from a single experiment performed in triplicate, error bars = SD. G) A table comparing the IC50 values from DMSO compound solutions prepared by Enamine and DMSO solutions prepared from powders (provided by Enamine) in Cardiff. H) Bar charts show the percentage αsignal inhibition of compounds at 0.1, 1 and 10 µM, for three separate protein-protein interactions: LAG-3-HLA-DR1 (“DR1 vs LAG-3”), HLA-A2-TCR (“A2 vs TCR”) and L243-HLA-DR1 (“DR1 vs L243”). Percentage αsignal inhibition was determined using the average αsignal of wells treated with DMSO only. Data is a representative of a minimum of 2 assay repeats. Figure 9 I) inhibition of LAG-3:Fc induced CCL4 production by THP-1 cells when treated with serially diluted compounds (5µM 1 in 2 dilution series). I) CCL4 pg / mL by THP-1 cells treated with hit compounds 68, 70, 75, J) corresponding percentage inhibition of CCL4 production. In Figures 9A and 9F, the topmost line is for compound 68. In Figures 9C and 9H, the bars in order from left to right of each of the “DR1 vs LAG-3”,“A2 vs TCR” and “DR1 vs L243” graphs are as follows: 0.1 µM, 1 µM, and 10 µM. In Figures 9D and 9I, the lines in anticlockwise order from the bottom of the graph are for compounds 68, 92, 70, 75, 93, and 94. In Figures 9E an 9J, the lines in order of appearance from left to right above the horizontal axis are for compounds 68, 92, 70, 75, 93, and 94. Figure 10A shows the Enamine screen hit compounds 68, 92, 69, 75 and 70 inhibit binding of a monomer formulation to LAG-3 binding to HLA-DR1. Figure 10B shows the Enamine screen hit compounds 68, 69, 75 and 70 inhibit binding of a monomer formulation to LAG-3 binding to HLA-DR1. Figure 11 shows the AlphaScreen data for compound 3 of the present invention. Data average of a minimum of three technical repeats. In Figure 11, the bars in order from left to right of each of the “DR1 vs LAG-3”,“A2 vs TCR” and “DR1 vs L243” graphs are as follows: 0.1 µM, 1 µM, and 10 µM. Figure 12A shows hit compounds 69, 80, 68, 51 and 12 with chemical scaffold identified by HTVS. Figure 12B shows hit compound 12 with chemical scaffold identified by HTVS. Figure 12C shows hit compounds 69, 68 with chemical scaffold identified by HTVS. Figure 13 shows pharmacophore models A) and B) and designed compounds according to the two models C). Figure 13 shows pharmacophore models D) and E) and designed compounds according to the two models F). Figure 14 shows a visual representation of the structural features that have a high impact on biological activity. Figure 15A shows compounds according to the present invention were solubilized in DMSO and a 3 point 1 in 10 serial dilution, 0.2, 2 and 20 µM was analysed by AlphaScreen for blockade of LAG-3:Fc binding to HLA-DR1 (blue) and non-specific blockade of L243 for HLA- DR1 (red), n = 4, error bars = SD. Figure 15B shows compounds according to the present invention were solubilized in DMSO and a 3 point 1 in 10 serial dilution, 0.2, 2 and 20 µM was analysed by AlphaScreen for blockade of LAG-3:Fc binding to HLA-DR1 (blue) and non-specific blockade of L243 for HLA- DR1 (red), n = 4, error bars = SD. Figure 15C shows compounds according to the present invention were solubilized in DMSO and a 3 point 1 in 10 serial dilution, 0.2, 2 and 20 µM was analysed by AlphaScreen for blockade of LAG-3:Fc binding to HLA-DR1 (blue) and non-specific blockade of L243 for HLA- DR1 (red), n = 4, error bars = SD. Figure 16A shows dose response determined for some of the most active compounds according to the present invention. A 10 point 1 in 2 serial dilution was prepared and analysed by AlphaScreen for blockade of LAG-3:Fc binding to HLA-DR1. Data average of two independent experiments, n = 4, errors bars = SD. Figure 16B shows dose response determined for some of the most active compounds according to the present invention. A 10 point 1 in 2 serial dilution was prepared and analysed by AlphaScreen for blockade of LAG-3:Fc binding to HLA-DR1. Data average of two independent experiments, n = 4, errors bars = SD. Figure 16C shows dose response determined for some of the most active compounds according to the present invention. A 10 point 1 in 2 serial dilution was prepared and analysed by AlphaScreen for blockade of LAG-3:Fc binding to HLA-DR1. Data average of two independent experiments, n = 4, errors bars = SD. Figure 17 shows the results of inhibition of THP-1 cells activation by IMP321 (20ng / ml) in the presence of different concentrations of compounds 1, 14, 16, and 20. Figure 18 shows the effects of compounds 1, 14, 16, and 20 on the binding of an anti-LAG- 3 Ab to a well-characterized conformational epitope in the D1 domain of LAG-3. Figure 19 shows that compound 20 blocks the LAG-3 / MHC class II interaction. DETAILED DESCRIPTION OF THE INVENTION Definition of terms MHC Class II molecules are a class of major histocompatibility complex (MHC) molecules normally found on professional antigen-presenting cells (APC). In humans, the MHC class II protein complex is encoded by the human leukocyte gene complex (HLA). HLAs corresponding to MHC class II are HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, and HLA-DR. Unless otherwise defined, all the technical and scientific terms used have the same meaning as that usually understood by an ordinary specialist in the field to which the invention belongs. Method of synthesis Compounds according to the present invention may be synthesised in line with one of the reactions schemes outlined below. The reaction schemes may be modified according to the teachings of the specification and / or methods routine in the art in order to synthesise compounds according to the present invention. Compounds according to the present invention may be synthesised via an amide coupling method according to the reaction scheme below. The compound 3 acid starting material was first activated using the coupling reagent, TBTU, under alkaline conditions. Subsequently, the amine was added, and the solution was mixed at room temperature overnight under inert conditions. The products were characterised by UPLC-QDa and purified to > 90% by normal- phase flash chromatography or trituration depending on the solubility and stability of the compounds. Additional characterisation of the pure products was performed by 1H-NMR and 13C-NMR. Compounds according to the present invention may be synthesised according to the reaction scheme below.
[0012] Compounds according to the present invention may be synthesised according to the reaction scheme below. Some of the compounds according to the present invention may also be obtained from small molecules libraries provided by Exquiron (Basel, Switzerland), Enamine or ChemDiv, that were available at the priority date of the present application. Analysis of Inhibition of LAG-3 MHC-II protein-protein interaction In total, 120,550 compounds were screened to determine their ability to inhibit the protein- protein interaction (PPI) of LAG-3 binding to key ligand major histocompatibility complex (MHC)-II. The compounds according to the present invention were shown to be potent and specific inhibitors of LAG-3 binding to human leukocyte antigen (HLA)-II. The compounds according to the present invention were shown to blockade not only against the well-established PPI between LAG-3:Fc and HLA-DR1, where LAG-3 is a dimeric molecule (two extracellular domains of LAG-3 covalently bound to a human IgG1 Fc) but, also a monomeric LAG-3 construct. By demonstrating blockade of two formulations of LAG- 3, it has been showed that these compounds are inhibiting the interaction between LAG-3 and HLA-DR1. Furthermore, it has been demonstrated that compound blockade is not limited to HLA-DR1, as compounds were also active against HLA-DR4 and HLA-DQ8 HLA-II molecules. Thus, it has been demonstrated that compounds of the present invention specifically block LAG-3:HLA-II using a multitude of different LAG-3:HLA-II configurations. Surprisingly, compounds of the present invention were also found to block FGL1 binding to LAG-3:Fc despite evidence for distinct binding sites on LAG-3 for HLA-II and FGL1. The assay screening of compounds of the present invention was done using Amplified Luminescent Proximity Homogeneous Assay (AlphaScreen, Perkin Elmer). AlphaScreen assay Amplified Luminescent Proximity Homogeneous Assay (AlphaScreenTM, Perkin Elmer) is microplate bead-based proximity assay for the detection of PPI. When a biological interaction brings the beads together, laser activation of a “donor” bead converts ambient oxygen to a singlet oxygen molecules. The short lived oxygen radical diffuse across to react with a thioxene derivative in the “acceptor” bead generating chemiluminescence at 370 nm that activates fluorophores to emit light at 520-620 nm. Working protein and bead solutions were prepared using AlphaLISA Universal buffer (Perkin Elmer) supplemented with 0.5 % Bovine Serum Albumin (BSA - Sigma), performed in 96 well 1 / 2 area white Optiplates (Perkin Elmer) and luminescence, referred to as in arbitrary units as alpha signal, detected using an En- Vision Excite plate reader (Perkin Elmer). All data were processed using Excel (Microsoft Corp., Redmond, WA), Prism (GraphPad Software, La Jolla, CA) or Python. Cross Titration A cross titration was used to determine the optimal protein concentration, to ensure a sufficient signal was generated whilst avoiding saturation known as the ‘hooking’ effect, in accordance with the manufacturer’s protocol (PerkinElmer). Streptavidin donor beads and protein A acceptor beads (product number 6760617) were used to bind to biotinylated pHLA- II and LAG-3:Fc (human IgG1 fusion protein) respectively. This was found to be 1 nM LAG- 3:Fc and 8 nM pHLA-DR1 (HLA-DRA*0101, HLA-DRB1:01 refolded with peptide HA305-319 derived from influenza A virus haemagglutinin in house). For the monomeric LAG-3:HLA- DR1 cross titration LAG-3 with a poly histidine tag (Bio-Techene) streptavidin donor beads and nickel chelate (product number 6760619) were used. Screen 1 – Aptuit / Exquiron Screen 50,000 compounds were initially screened to determine their ability to inhibit LAG-3 binding to HLA-II. Compound screening was performed in a final reaction volume of 40 µL and compounds were pooled into pools of 5 compounds. The final concentration for each individual compound was 8 µM. The library was screened as follows: Optiplates pre-loaded with 1uL of a DMSO pooled compound solution (200 nL of each individual compound) were centrifuged at 400 x g for 5 minutes. In the dark, 4 X working solutions of each protein and bead component were prepared and thoroughly mixed before loading into the Optiplate. Plates were sealed and incubated under agitation at room temperature for 1 hour before alpha signal was measured using an En-Vision plate reader (Perkin Elmer). Each Optiplate plate included the following controls: 3 wells loaded with 1 µL DMSO alone (to calculate compound signal inhibition) and 2 wells containing pHLA-I to calculate background, as well as a single well containing beads alone and a single well containing anti-LAG-3 Fab fragments as a positive control. Subsequent assays screening compounds individually used the same assay conditions described above. All HLA molecules were generated in-house apart from HLA-DQ8-glia-α1 (DQA1*0301, DQB1*0302) which was kindly provided by Ludvig Sollid. Biochemical (TruHits) and biological compound validation assays TruHits Kit (product code 6760627) (Perkein Elmer) which contained streptavidin donor beads and biotinylated acceptor beads permitted elimination of hit compound pools which interfered with the assay chemistry. TruHit screening validation was performed in a final reaction volume of 20 µL, test compound concentration 16 µM (pools of 5 compounds) according to manufacturer’s instruction and relative inhibition to a DMSO only control was used to eliminate false active wells. An irrelevant PPI of similar predicted affinity was used to validate hit compound pools. A TCR specific for a pHLA-I complex was selected, where the TCR had a polyhistidine-tag and the pHLA-I was biotinylated, which bound to nickel chelate acceptor beads and streptavidin donor beads respectively (product code 6760619). Biological screening was performed in the same manner as previously described for compound screening. FGL1 To detect binding of a polyhistidine-tagged FGL1 (Sino Biological) to LAG-3:Fc, a nickel chelate donor and protein A acceptor bead configuration was used (Perkin Elmer). A cross titration was performed as described previously, to determine optimal screening concentrations of 1 nM LAG-3:Fc and 30 nM FGL1. Compounds were then screened against the FGL1:LAG-3:Fc interaction in parallel to HLA-DR1:LAG-3:Fc, as well as irrelevant PPI of anti-DR mAb L243 (bound to protein A acceptor) and HLA-DR1 (bound to streptavidin donor beads). LAG-3:Fc potency assay The monocytic cell line THP-1 (ATCC® TIB-202TM) expresses HLA-II, specifically DRB1*01, DRB1*15; DRB5*01 / 02; DQB1*05, DQB1*06. When LAG-3:Fc binds to HLA-II on the cell surface this results in activation and secretion of the chemokine CCL4 (MIP-Iβ). THP-1 cells were seeded (20,000 per well) and subsequently treated with LAG-3:Fc (75 ng / mL) previously incubated with a dilution series of compounds. Supernatants were collected after 4 hours incubation at 37°C and 5% CO2and CCL4 secretion measured by ELISA (R & D Systems). Percentage CCL4 inhibition was calculated relative to DMSO only treated cells. LAG-3:HLA-DR1 can be impinged upon by compounds according to the present invention Initially a protein cross titration was performed to determine optimal conditions for the screen (Figure 1A). For HLA-DR1 and LAG3:Fc the optimal ratio of concentrations fell between 3 and 10 nM and 0.3 and 3 nM respectively; to avoid the hooking effect yet still obtain substantial alpha signal for high signal to background ratio, we chose concentration of 8 nM for HLA-DR1 and 1 nM for LAG-3-Fc. Using these optimal concentrations of LAG-3:Fc and HLA-DR1, a small molecule library of 50,000 pooled compounds was screened for their ability to block this interaction (schemata shown in Figure 1B). The screen identified 221 active compound pools (alpha signal blockade >70%), 170 of which inhibited alpha signal >80%, and 116 of which inhibited alpha signal >90% (Figure 1C). The total number of active wells identified by the screen was therefore 2.21% (>70% alpha signal blockade). The 221 active wells which resulted in >70% alpha signal inhibition were validated using a TruHit assay to eliminate false hits which interfered with AlphaScreenTMbead chemistry (Figure 1D). Active wells were also screened against an irrelevant PPI, a TCR for a cognate pMHC-I, of similar affinity to that predicted for LAG-3:Fc:HLA-II, to eliminate non-specific effects (Figure 1E). As a result, a total of 57 compound pools were eliminated. Next, the top 100 active wells, from the remaining 164, were selected for deconvolution by ranking in order of: 1) highest percentage LAG-3:HLA-DR1 inhibition, 2) lowest percentage inhibition of the TruHit alpha signal and 3) lowest percentage inhibition of the irrelevant PPI. Deconvolution of pooled compounds demonstrated that in all but two active wells, a single compound was responsible for LAG-3:HLA-DR1 inhibition (Figure 1F). For one active well there were two active compounds with moderate activity; one blocking at 24% and the other 46%, with the original pool having demonstrated 87% inhibition. There was also a single well where no active compound was identified during deconvolution. The 50 most potent compounds were selected for further analysis. A dose response assessment of these selected compounds determined eight compounds - compounds 91, 25, 81, 79, 27, 78, 77 and 74 of the present invention which demonstrated titratable blockade (Figure 2A). A dose response assessment of these selected compounds determined compounds 25 and compounds 27 of the present invention which demonstrated titratable blockade (Figure 2B). A dose response assessment of these selected compounds determined eight compounds including compound 81 of the present invention which demonstrated titratable blockade (Figure 2C). A dose response assessment of these selected compounds determined eight compounds including compounds 78, 77 and 74 of the present invention which demonstrated titratable blockade (Figure 2D). Monomeric LAG-3 binding to HLA-DR1 is similarly blocked by compounds of the invention Next, it was explored whether the blocking of LAG-3:Fc binding to HLA-DR1 was affected by the dimeric nature of the LAG-3:Fc construct. To address this question, monomeric LAG-3 construct was purchased with a poly-His tag; like LAG-3:Fc this formulation is manufactured using Chinese hamster ovary [CHO] cells. Using a nickel chelate acceptor and streptavidin donor bead configured AlphaScreenTMassay, it was demonstrated that this formulation of monomeric LAG-3 (referred to in this study as LAG-3His) bound similarly to HLA-DR1 (Figure 3A) and importantly, compounds 91, 81, 79, 78, 77 and 74 according to the present invention were able to inhibit this interaction (Figure 3B). Using a nickel chelate acceptor and streptavidin donor bead configured AlphaScreenTMassay, it was demonstrated that this formulation of monomeric LAG-3 (referred to in this study as LAG-3His) bound similarly to HLA-DR1 (Figure 3A) and importantly, compound 81 according to the present invention was able to inhibit this interaction (Figure 3C). Using a nickel chelate acceptor and streptavidin donor bead configured AlphaScreenTMassay, it was demonstrated that this formulation of monomeric LAG-3 (referred to in this study as LAG-3His) bound similarly to HLA-DR1 (Figure 3A) and importantly, the compounds according to the present invention were able to inhibit this interaction (Figure 3D). Compound of the present invention block LAG-3 binding to multiple-HLA-II subtypes The dose response assays were validated in repeat assays against HLA-DR1 (Figure 4A and Figure 5B) with similar LAG-3:Fc blocking capacity also demonstrated against HLA-DR4 (HLA-DRA*0101, HLA-DRB1:04, binding same HA peptide) and HLA-DQ8-glia-α1 (DQA1*0301, DQB1*0302) (Figures 4B-C). Serial dilutions enabled accurate IC50sto be calculated, ranging from 3.24 µM for compound 78 and 1.94 µM for compound 81 (Figure 4D). A Luminex bead-based assay was performed as a positive control for a recent study, where they showed that LAG-3:Fc bound to the 95 HLA-II alleles, but with some variable binding demonstrated between subtypes. Therefore, we determined the efficacy of hit compound inhibition with additional HLA-DR-II molecules. Not only did the dose response curves appear very similar for all compounds 91, 81, 79, 78, 77 and 74, but the calculated IC50s were consistent across the three HLA subtypes (Figure 4D). The dose response assays were validated in repeat assays against HLA-DR1 (Figure 4E and Figure 5F) with similar LAG-3:Fc blocking capacity also demonstrated against HLA-DR4 (HLA-DRA*0101, HLA-DRB1:04, binding same HA peptide) and HLA-DQ8-glia-α1 (DQA1*0301, DQB1*0302) (Figures 4F-G). Serial dilutions enabled accurate IC50sto be calculated (Figure 4H). A Luminex bead-based assay was performed as a positive control for a recent study, where they showed that LAG-3:Fc bound to the 95 HLA-II alleles, but with some variable binding demonstrated between subtypes. Therefore, we determined the efficacy of hit compound inhibition with additional HLA-DR-II molecules. The dose response assays were validated in repeat assays against HLA-DR1 (Figure 4I and Figure 5H) with similar LAG-3:Fc blocking capacity also demonstrated against HLA-DR4 (HLA-DRA*0101, HLA-DRB1:04, binding same HA peptide) and HLA-DQ8-glia-α1 (DQA1*0301, DQB1*0302) (Figures 4J-K). Serial dilutions enabled accurate IC50s to be calculated (Figure 4L). A Luminex bead-based assay was performed as a positive control for a recent study, where they showed that LAG-3:Fc bound to the 95 HLA-II alleles, but with some variable binding demonstrated between subtypes. Therefore, we determined the efficacy of hit compound inhibition with additional HLA-DR-II molecules. Not only did the dose response curves appear very similar for all compounds, but the calculated IC50swere consistent across the three HLA subtypes (Figure 4L). Compounds of the present invention block LAG-3 binding to FGL1 In 2019 Wang and colleagues showed that LAG-3 also bound to Fibrinogen-like protein 1 (FGL1), a protein secreted by the liver which belongs to the fibrinogen family. Therefore we also screened hit compounds against the interaction between LAG-3:Fc and FGL1 interaction via AlphaScreenTMutilising FGL1His. We first demonstrated that the FGL1 and LAG-3:Fc interaction was detected by AlphaScreenTMusing a cross titration (Figure 5A). To screen compounds against this PPI and using a Nickle Chelate bead configuration, a greater quantity of FGL1His (30 nM) was required to obtain optimal signal counts using the same amount of LAG-3:Fc (1 nM). All of compounds 91, 25, 81, 79, 27, 78, 7 and 74 blocked FGL1 binding (Figure 5B). These results confirm the compounds bind directly to LAG-3, and suggest this causes a conformation shift which impacts on both HLA-II and FGL1 binding. We first demonstrated that the FGL1 and LAG-3:Fc interaction was detected by AlphaScreenTMusing a cross titration (Figure 5C). To screen compounds against this PPI and using a Nickle Chelate bead configuration, a greater quantity of FGL1His (30 nM) was required to obtain optimal signal counts using the same amount of LAG-3:Fc (1 nM). Compound 25 and 27 blocked FGL1 binding (Figure 5D). These results confirm the compounds bind directly to LAG-3, and suggest this causes a conformation shift which impacts on both HLA-II and FGL1 binding. We first demonstrated that the FGL1 and LAG-3:Fc interaction was detected by AlphaScreenTMusing a cross titration (Figure 5E). To screen compounds against this PPI and using a Nickle Chelate bead configuration, a greater quantity of FGL1His (30 nM) was required to obtain optimal signal counts using the same amount of LAG-3:Fc (1 nM). Compound 81 blocked FGL1 binding (Figure 5F). These results confirm the compounds bind directly to LAG-3, and suggest this causes a conformation shift which impacts on both HLA-II and FGL1 binding. We first demonstrated that the FGL1 and LAG-3:Fc interaction was detected by AlphaScreenTMusing a cross titration (Figure 5G). To screen compounds against this PPI and using a Nickle Chelate bead configuration, a greater quantity of FGL1His (30 nM) was required to obtain optimal signal counts using the same amount of LAG-3:Fc (1 nM). All the hit compounds blocked FGL1 binding (Figure 5H). These results confirm the compounds bind directly to LAG-3, and suggest this causes a conformation shift which impacts on both HLA-II and FGL1 binding. Compounds of the present invention inhibit LAG-3:Fc activation of APCs Although best known as a T-cell inhibitory co-receptor, soluble LAG-3:Fc has been shown to activate antigen presenting cells (APCs), binding to surface HLA-II and inducing secretion of CCL4 (MIP-1β). Small molecule inhibition of LAG-3:Fc induced APC activation was used to examine the potency of hit compounds, by measuring CCL4 (MIP-1β) secretion by THP-1 cells. Compounds 81, 79, 78 and 77 were demonstrated to be potent blockers of LAG-3:Fc binding to THP-1 expressed HLA-II molecules demonstrating complete abrogation of CCL4 production (Figure 6A-C). Compounds 25 and 27 were demonstrated to be potent blockers of LAG-3:Fc binding to THP- 1 expressed HLA-II molecules demonstrating complete abrogation of CCL4 production (Figure 6D-E). Compound 81 demonstrated to be potent blocker of LAG-3:Fc binding to THP-1 expressed HLA-II molecules demonstrating complete abrogation of CCL4 production (Figure 6F-H). All compounds bar compound 74 were demonstrated to be potent blockers of LAG-3:Fc binding to THP-1 expressed HLA-II molecules demonstrating complete abrogation of CCL4 production (Figure 6I-K). The assays performed in relation to Screen 1 demonstrate that the binding of soluble LAG-3 to cell surface HLA-II can be potently inhibited by compound according to the present invention. Screen 2 – Aptuit analogues screen In Screen 2, 440 analogues of the hit compounds identified in Screen 1 were screened using the AlphaScreen assay to determine their activity against LAG-3:HLA-II. Dose response assays were performed on the 6 most active compounds identified from the analogue screen: Compounds 12, 17, 19 and 21, 51, 80 (Figure 7A) which showed they were potent analogues (Figure 7B). Dose response assays were performed on the most active compounds identified from the analogue screen: Compound 12, 17, 19 and 21 (Figure 7C) which showed they were potent analogues (Figure 7D). Dose response assays were performed on the most active compound identified from the analogue screen: Compound 80 (Figure 7E). Dose response assays were performed on the most active compound identified from the analogue screen: Compound 51 (Figure 7G). Screen 3 – Enamine screen In Screen 3, 40,000 compounds were screened using the AlphaScreen assay to determine their activity against LAG-3:HLA-II. Compounds were pooled into 5 compounds per well and screened at a final concentration of 5 µM against LAG-3 and HLA-DR1 using AlphaScreenTM (Figure 8A). Twenty-six active wells demonstrated activity greater than 90% (Figure 8B). Deconvolution of these active wells identified 7 hit compounds as more potent than previous hits (compounds 91, 25, 27, 81, 79, 27, 78, 77 and 74), with the majority of active wells demonstrating a single compound was responsible for inhibiting the interaction (Figure 8C and D). A TruHit (Perkin Elmer) assay was performed to identify compounds which interfere with the assay rather than the protein-protein interaction of interest, i.e., a false hit. By adding compounds to pre-mixed TruHit AlphaScreenTM beads (which bind without the presence of tagged proteins via their Streptavidin and biotin coatings), compounds which interfere with the assay chemistry (including light scatters, singlet oxygen quenchers) were eliminated (Figure 8E) and the most potent hits (compounds 68, 69, 70, 75, 92, 93 and 94) identified by dose response assay (Figure 8F). The Screen 3 hits were validated using fresh powder stocks of the seven compounds and dose response assays were repeated (Figure 9A). All compounds showed similar activity however, for compound 93 the IC50 reduced from 1.82 to 12.27 µM (Figure 9B). When the specificity assays were performed (TCR:pHLA-A2 & L234:HLA-DR, described previously), it became apparent that whilst compound 92, compound 68, compound 70 did not demonstrate any non-specific binding or assay inhibition at 10 µM, compound 69, compound 94 and compound 93 inhibited both L243 binding to HLA-DR1 and cognate TCR binding to pHLA- A2 by up to 20% (Figure 9C). This suggested these compounds inhibited the AlphaScreenTM assay, as indicated by the TruHit results (Figure 8E). In the case of compound 75, L243 and HLA-DR1 binding was not inhibited, yet TCR binding to pHLA-A2 was inhibited by >20%, perhaps suggesting that compound 75 was only capable of interfering of with a PPI of similar affinity or the different bead configuration. Interestingly, all Screen 3 hits (compounds 68, 92, 69, 75 and 70) were able to inhibit a second monomeric formulation of LAG-3, a LAG-3 with a poly histidine tag (BioTechne), from binding to HLA-DR1 (Figure 10). When these hit compounds were analysed for their ability to inhibit LAG-3:Fc induced activation of THP-1 cells via binding to cell surface HLA-II (Figure 9D), the most potent compound was compound 68 (Figure 9E). Compound 75 only demonstrated 60% inhibition at 5 µM and compounds 94 and 95 which previously demonstrated non-specific blockade via AlphaScreenTM showed no activity in this assay (Figure 9E). Thus, compound 68 was deemed the most potent and specific hit of the Screen 3. In Screen 3, 40,000 compounds were screened using the AlphaScreen assay to determine their activity against LAG-3:HLA-II. Compounds were pooled into 5 compounds per well and screened at a final concentration of 5 µM against LAG-3 and HLA-DR1 using AlphaScreenTM (Figure 8A). Twenty-six active wells demonstrated activity greater than 90% (Figure 9G). Deconvolution of these active wells identified 7 hit compounds as more potent than previous hits (compounds 78, 77 and 74), with the majority of active wells demonstrating a single compound was responsible for inhibiting the interaction (Figure 8C and D). A TruHit (Perkin Elmer) assay was performed to identify compounds which interfere with the assay rather than the protein-protein interaction of interest, i.e., a false hit. By adding compounds to pre- mixed TruHit AlphaScreenTM beads (which bind without the presence of tagged proteins via their Streptavidin and biotin coatings), compounds which interfere with the assay chemistry (including light scatters, singlet oxygen quenchers) were eliminated (Figure 8G) and the most potent hits identified by dose response assay (Figure 8H). The Screen 3 hits were validated using fresh powder stocks of the seven compounds and dose response assays were repeated (Figure 9F). All compounds showed similar activity (Figure 9G). When the specificity assays were performed (TCR:pHLA-A2 & L234:HLA-DR, described previously), it became apparent that whilst compound 68, compound 70 did not demonstrate any non-specific binding or assay inhibition at 10 µM, compound 69, inhibited both L243 binding to HLA-DR1 and cognate TCR binding to pHLA-A2 by up to 20% (Figure 9H). This suggested these compounds inhibited the AlphaScreenTM assay, as indicated by the TruHit results (Figure 9J). In the case of compound 75, L243 and HLA-DR1 binding was not inhibited, yet TCR binding to pHLA-A2 was inhibited by >20%, perhaps suggesting that compound 75 was only capable of interfering of with a PPI of similar affinity or the different bead configuration. Interestingly, all Screen 3 hits were able to inhibit a second monomeric formulation of LAG-3, a LAG-3 with a poly histidine tag (BioTechne), from binding to HLA- DR1 (Figure 10). When these hit compounds were analysed for their ability to inhibit LAG-3:Fc induced activation of THP-1 cells via binding to cell surface HLA-II (Figure 9I), the most potent compound was compound 68 (Figure 9J). Compound 75 only demonstrated 60% inhibition at 5 µM (Figure 9J). Thus, compound 68 was deemed the most potent and specific hit of the Screen 3. Screen 4 – Further compounds were screened based on pharmacophores of interest identified in the previous screens. Compound 3 demonstrated comparable activity to previous hit compounds. Compound 3 was found to be a potent and specific inhibitor of LAG-3 / HLA-DR1, yet unable to block a cognate TCR pHLA-A2 interaction as well as L243 for HLA-DR1 (Figure Screen 5 – In silico workflow High-Throughput Virtual Screening (HTVS) was performed, and the biological results identified 5 different active scaffolds (Figure 12A) – corresponding to compounds 12, 51, 68, 69 and 80. High-Throughput Virtual Screening (HTVS) was performed, and the biological results identified an active scaffold corresponding to compound 12 (Figure 12B). High-Throughput Virtual Screening (HTVS) was performed, and the biological results identified different active scaffolds (Figure 7F) – corresponding to compound 80. High-Throughput Virtual Screening (HTVS) was performed, and the biological results identified active scaffolds (Figure 12) – corresponding to compound 51. High-Throughput Virtual Screening (HTVS) was performed, and the biological results identified 5 different active scaffolds (Figure 12C) – corresponding to compounds 68, 69 Interestingly, recurring structural motifs in the biologically active compounds were identified, such as sulfonyl and amide groups. To facilitate the investigation of the structure-activity relationships for those compounds, a series of pharmacophore-model hypotheses were built. These models can identify a common template for the active compounds, which can potentially predict active compounds and guide the synthesis for novel and more potent analogues. The pharmacophore models were generated by analysing the diverse molecules fields of each molecule, such as positive and negative electrostatic fields, van der Waals shape, hydrophobic fields, and their spatial distribution. Up to 200 different spatial conformations for each compound have been generated. They were then aligned according to the calculated field point to find common electrostatic and hydrophobic motifs. The results showed two possible pharmacophore models (Figure 13A, B). Model A showed the highest electrostatic similarity (score: 0.57), while model B showed the highest shape similarity (score 0.68). There are some overlapping structural motifs for both models, which can point out the possible "exchangeable" functional groups of active compounds. According to these models, we have then applied a "cut and paste" strategy, breaking up the active molecules into fragments and mixing the different fragments together.3 different compounds have been designed according to this strategy – compounds 39, 95 and 96 (Figure 13C). The results showed two possible pharmacophore models (Figure 13D, E). Model D showed the highest electrostatic similarity (score: 0.57), while model E showed the highest shape similarity (score 0.68). There are some overlapping structural motifs for both models, which can point out the possible "exchangeable" functional groups of active compounds. According to these models, we have then applied a "cut and paste" strategy, breaking up the active molecules into fragments and mixing the different fragments together. Compounds 39 and 51 have been designed according to this strategy (Figure 13F). Compound 39 is shown to provide moderate activity (Figure 15B). In parallel, we have also generated a 3D-QSAR model based on the biological activity of the "pyrrole family" (compound 12 analogue and compound 3), which showed a higher number of active compounds than other families. The QSAR was built by analysing 620 diverse physicochemical and topological properties of compound 12 analogues (such as hydrogen bond donator / acceptor, topological surface area, hydrophobicity etc.) to create a predictive model that correlates the calculated properties with the compounds’ biological activity. The predictive ability of the derived 3D-QSAR model was confirmed by leave-one-out (LOO) technique, analysing the r2, q2 value and the root-mean-square error (RMSE) of the predictive model. The test model showed good predictive and descriptive capabilities: r2 (0.83) and q2 (0.56) values, and by the low RMSE (0.12). This model revealed different structural and property features that appear to have a relatively high impact on biological activity. In particular, the presence of an electron-withdrawing group (EWG) and a hydrogen bond donating (HBD) (i.e., amide, acid, and sulfonamide) in the benzyl ring, and the length of the linker between the pyrrole-phenyl core and benzyl ring (no more than 2 methylene group) can drastically affect the biological activity of these family (Figure 14). This model was used to screen a series of novel designed compounds to select the most promising compounds which were screened alongside other novel compounds of interest. According to the results, two compounds have been designed, which showed a very promising activity (compound 1 and compound 9) (Figures 15, 15A and 16, 16A). For this reason, we have prioritized the development of the pyrrole family (hit rates = 52.3%), where we have higher probability to identify a novel and more potent compound in comparison to the other two families. Screen 6 – Late synthesis Amine compounds were synthesised according to the reaction scheme outlined previously. The choice of amines was based on previous hit compounds and structural features showing high activity in the pharmacophore models. Such features include electron-withdrawing / - donating groups (EWGs / EDGs), linker groups, and aromatic / heteroaromatic groups that could potentially improve specific LAG-3 affinity and inhibition through H-bonding interactions, π-π interactions and hydrophobic interactions with amino acid residues at the LAG-3 binding sites (Figures 13 and 14). Some of the synthesised compounds consist of a combination of different compound families showing sulfonamide and thiazole features. These compounds were based on 3 hit compounds, namely, compound 12, 68 and 69. The focus was mainly on the pyrrole family as the screening of analogues of the other families did, so far, not demonstrate an increase in activity. The compounds were screened by AlphaScreen for blockade of LAG-3:Fc binding to HLA- DR1 and non-specific blockade of L243 for HLA-DR1, and the results are shown in Figure 15A. Further, AlphaScreen dose response assays for blockade of LAG-3:Fc binding to HLA-DR1 were performed for the most active compounds identified in the Screens 1 to 6 of the present invention. The results are shown in Figure 16A. These compounds were based on hit compounds including compound 12. The focus was on the pyrrole family as the screening of analogues of the other families did, so far, not demonstrate an increase in activity. The compounds were screened by AlphaScreen for blockade of LAG-3:Fc binding to HLA- DR1 and non-specific blockade of L243 for HLA-DR1, and the results are shown in Figure 15B. Further, AlphaScreen dose response assays for blockade of PAG-3:Fc binding to HLA-DR1 were performed for the most active compounds identified in the Screens of the present invention. The results are shown in Figure 16B. These compounds were based on 2 hit compounds, namely, 68 and 69. The focus was mainly on the pyrrole family as the screening of analogues of the other families did, so far, not demonstrate an increase in activity. The compounds were screened by AlphaScreen for blockade of LAG-3:Fc binding to HLA- DR1 and non-specific blockade of L243 for HLA-DR1, and the results are shown in Figure 15C. Further, AlphaScreen dose response assays for blockade of PAG-3:Fc bnding to HLA-DR1 were performed for the most active compounds identified in the Screens of the present invention. The results are shown in Figure 16C. EXAMPLES Synthesis Exemplified compound 37 may be obtained by the reaction scheme outlined below: Other compounds according to the present invention may be synthesised using a reaction scheme similar to the one outlined above, but modified in line with teachings of the specification and / or methods routine in the art. LAG-3 inhibition data for compounds 1 to 90 Compounds according to the present invention were screened by AlphaScreen for blockade of LAG-3:Fc binding to HLA-DR1. Table 1 below indicates the % signal blockade at a compound concentration of 20 µM for compounds 1 to 90. Table 1
[0013] The data in Table 1 demonstrates that compounds 1 to 90 according to the present invention are potent and specific inhibitors of LAG-3 binding to HLA-DR1. LAG-3 inhibition data for compounds 1 to 50 Compounds according to the present invention were screened by AlphaScreen for blockade of LAG-3:Fc binding to HLA-DR1. Table 2 below indicates the % signal blockade at a compound concentration of 20 µM for compounds 1 to 50. Table 2 The data in Table 2 demonstrates that the compounds according to the present invention are potent and specific inhibitors of LAG-3 binding to HLA-DR1. LAG-3 inhibition data for compounds 80 to 90 Compounds according to the present invention were screened by AlphaScreen for blockade of LAG-3:Fc binding to HLA-DR1. Table 3 below indicates the % signal blockade at a compound concentration of 20 µM for compounds 80 to 90. Table 3 The data in Table 3 demonstrates that compounds 80 to 90 according to the present invention are potent and specific inhbitors of LAG-3 binding to HLA-DR1. LAG-3 inhibition data for compounds 51 to 67 Compounds according to the present invention were screened by AlphaScreen for blockade of LAG-3:Fc binding to HLA-DR1. Table 4 below indicates the % signal blockade at a compound concentration of 20 µM for compounds 51 to 67. Table 4 The data in Table 4 demonstrates that compounds 51 to 67 according to the present invention are potent and specific inhbitors of LAG-3 binding to HLA-DR1. LAG-3 inhibition data for compounds of the present invention Compounds according to the present invention were screened by by AlphaScreen for blockade of LAG-3:Fc binding to HLA-DR1. Table 5 below indicates the % signal blockade at a compound concentration of 20 µM for compounds 68, 69, 70, 73, 74, 75, 77 and 78. Table 5
[0014] The data in Table 5 demonstrates that compounds according to the present invention are potent and specific inhbitors of LAG-3 binding to HLA-DR1. Inhibition of IMP321 (LAG-3Ig)-induced monocyte activation by compounds 1, 14, 16 and 20. IMP321 (LAG-3Ig) is able to activate cells of the human monocytic cell line THP-1 via its interaction with MHC Class II molecules. Activation of THP-1 cells can be determined by the level of secretion of chemokine ligand 4 (CCL4, also known as macrophage inflammatory protein-1β, MIP-1β). Pre-incubation of a compound with IMP321 prior to incubation of the mixture with THP-1 cells can be used to determine whether the compound inhibits the binding of LAG-3 to its natural receptors expressed on the cell surface and inhibits IMP321-induced monocyte activation. A method for determining inhibition of IMP321-induced monocyte activation is described in the example below. IMP321 (20 ng / ml) was preincubated with various concentrations of compounds for 10 minutes at RT, before incubation of the mixture with THP-1 cells for 4 hours at 37°C. The amount of CCL4 secretion by the THP-1 cells was used to determine the level of monocyte activation. The results are presented as the concentration of CCL4 in cell supernatant and as percentage of CCL4 inhibition in the presence of compounds. Figure 17 shows the results of inhibition of THP-1 cells activation by IMP321 (20ng / ml) in the presence of different concentrations of compounds 1, 14, 16, and 20.
[0015] It was concluded from these results, that compounds 1, 14, 16 and 20, inhibit the interaction of soluble LAG-3 with cell-expressed MHC II molecules and subsequent cell activation. Compounds 1 and 20 were the most active at inhibiting the interaction in this cell-based assay. Compounds 1 and 20 bind to D1 domain of LAG-3. D1 domain of LAG-3 is crucial for its interaction with MHC class II molecules. The effect of the compounds on the binding of an anti-LAG-3 Ab directed against well characterized conformational epitope in the D1 Domain was investigated. Key amino-acids involved in the binding of this Ab are located in 4 distinct discontinuous epitopes. LAG-3-transfected Jurkat cells were pre-incubated without or with saturating amount of compounds (500 µM), for 1 hour in PBS, BSA 0.5%, at 37°C. Then various concentrations of the FITC-conjugated anti- LAG-3 monoclonal antibody (IMP761) were added to the mix for 30min at 4°C in PBS, BSA 0.5%. The results are presented as the mean of fluorescence intensity (MFI) of FITC- conjugated anti-LAG-3 monoclonal antibody. Figure 18 shows the effects of compounds 1, 14, 16, and 20 on the binding of an anti-LAG- 3 Ab to a well-characterized conformational epitope in the D1 domain of LAG-3. It was concluded that pre-incubation with compounds 1 and 20 inhibits the binding of anti- LAG-3 IMP761 on Jurkat cells expressing LAG-3. This suggests that compounds 1 and 20 bind to a part of the D1 domain (the 4 discontinuous epitopes) recognized by IMP761. LAG-3 antagonist assay using LAG-3 / NFAT-luc2 transfected Jurkat T cells This method is based on the ability of the Jurkat T cell line co-transfected with LAG-3, and the luciferase gene under the control of the NFAT transcription factor, to be stimulated by the superantigen SEE presented by Raji B cells which are antigen presenting cells expressing MHC Class II. The combination of these two cell lines with SEE as superantigen induces the activation of NFAT promoter followed by luciferase-induced bioluminescence. As the Jurkat T cells express LAG-3 at their surface, the triggering of LAG-3 by MHC class II leads to mildly suppressed Jurkat T cell activation. In the presence of compound 20, to assess the effect of the compound on the inhibitory activity of the LAG-3 / MHC class II interaction, the LAG-3 negative signal is blocked leading to increased luminescence (RLU). Figure 19 shows the augmentation of luminescence normalized to positive and negative controls. This augmentation demonstrates that compound 20 blocks the LAG-3 / MHC class II interaction.
Claims
Claims 1.) A compound having the Formula (I):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: Z is 0 or 1; n is 0 or 1; m is 0 or 1; Y is selected from an alkyl group or a heteroalkyl group, wherein the alkyl group or heteroalkyl group may be substituted or unsubstituted; A is selected from CH2, CHCH3or CO; B is selected from a secondary or tertiary amine containing group; wherein when B is a secondary amine containing group, X is selected from an alkyl group or a heteroalkyl group, wherein the alkyl group or heteroalkyl group may be substituted or unsubstituted; wherein when B is a tertiary amine containing group, B and X together form a heteroalkyl or heteroaryl ring group, wherein the heteroalkyl or heteroaryl ring group may be substituted or unsubstituted; or B is selected from NH2or OH when m=0 and Z=0; R is selected from an aryl group or a heteroaryl group, wherein the aryl group or heteroaryl group may be subsituted or unsubsituted; wherein the compound having the Formula (I) does not comprise a -COCH2O- functional group.2.) A compound having the Formula (I):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: n is 0 or 1; m is 0 or 1; Y is selected from an alkyl group or a heteroalkyl group, wherein the alkyl group or heteroalkyl group may be substituted or unsubstituted; A is selected from CH2, CHCH3or CO; B is selected from a secondary or tertiary amine containing group; wherein when B is a secondary amine containing group, X is selected from an alkyl group or a heteroalkyl group, wherein the alkyl group or heteroalkyl group may be substituted or unsubstituted; wherein when B is a tertiary amine containing group, B and X together form a heteroalkyl or heteroaryl ring group, wherein the heteroalkyl or heteroaryl ring group may be substituted or unsubstituted; R is selected from an aryl group or a heteroaryl group, wherein the aryl group or heteroaryl group may be subsituted or unsubsituted; wherein the compound having the Formula (I) does not comprise a -COCH2O- linker groupbetween the two R groups. 3.) A compound according to claim 1 selected from compounds of the following formulae, and stereoisomeric forms and / or pharmaceutically acceptable salts thereof:4.) A compound having the Formula (II):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: n is 0 or 1; X is selected from a primary amine, a secondary amine, a tertiary amine or a hydoxyl group. 5.) A compound having the Formula (II):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: n is 0 or 1; X is selected from -OH, -NH2, -NHR1or -NR2R3; wherein R1is selected from an alkyl group or a heteroalkyl group which may optionally be substituted with an aryl group or a heteroaryl group, wherein the aryl group or heteroaryl group may be substituted or unsubstituted; wherein R2and R3are fused to form a heteroalkyl or heteroaryl ring group, wherein the heteroalkyl or heteroaryl ring group may be substituted or unsubstituted. 6.) A compound according to claims 4 or 5, wherein:X is selected from -OH, -NH2, -NHR1,, ; or R1represents a group of the formula:wherein: m is 0, 1 or 2; Y is selected from N or CH; W is selected from -SO2NH2, -OCH3, -COOH, -NHCOCH3, -CN, -OH, -CH3or -N(CH3)2, -CH2SO2CH3, -NHCONH2, F, H, -NHSO2CH3, -CONH2, -SO2N(CH3)2, -CH2SO2NH2, -CONHCH3or -CH2CN;or wherein R1represents a group of the formula: , ;wherein I is 0, 1 or 2; or wherein R1represents a group of the formula: , ,7.) A compound according to claim 4, selected from compounds of the following formulae, and stereoisomeric forms and / or pharmaceutically acceptable salts thereof:8.) A compound having the Formula (III):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: Z is 0 or 1;X is selected from CH3or H; A is selected from an alkyl group or a heteroalkyl group; R is selected from an aryl group, a heteroaryl group, an alkyl ring group or a heteroalkyl ring group, wherein the aryl group, heteroaryl group, alkyl ring group or heteroalkyl ring group may be subsituted or unsubsituted. 9.) A compound according to claim 8 having the formula (IV):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: Z is 0 or 1; X is selected from CH3or H; A is selected from an alkyl group or a heteroalkyl group; Y is selected from CH or N; R1 and R2 and each independently selected from NO2, SO2CH3, OCH3, Cl,10.) A compound according to claim 8 selected from compounds of the following formulae, and stereoisomeric forms and / or pharmaceutically acceptable salts thereof:11.) A compound having the Formula (V):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: wherein X is a tertiary amine ring group, wherein the tertiary amine ring group may be substituted or unsubstituted. 12.) A compound according to claim 11 having the formula (VI):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof, wherein: Z is 0 or 1; Y is selected from SO2, an alkyl group or an alkyl ether group; R1and R2are each independently selected from NO2, OCH3, OCH2CH3or F. 13.) A compound according to claim 11 selected from compounds of the following formulae, and stereoisomeric forms and / or pharmaceutically acceptable salts thereof:14.) A compound having the Formula (VII):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof. 15.) A compound having the Formula (VIII):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof.16.) A compound having the Formula (IX):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof. 17.) A compound having the Formula (X):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof. 18.) A compound having the Formula (XI):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof. 19.) A compound having the Formula (XII):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof. 20.) A compound having the Formula (XIII):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof. 21.) A compound having the Formula (XIV):or a stereoisomeric form and / or pharmaceutically acceptable salt thereof. 22.) A pharmaceutical composition comprising a compound according to any one of claims 1 to 21, and a pharmaceutically acceptable carrier and / or excipient. 23.) A compound according to any of claims 1 to 21, or a pharmaceutical composition according to claim 22, for use as a medicament. 24.) A compound, or a pharmaceutical composition, for use according to claim 23, wherein the compound is capable of binding to LAG-3. 25.) A compound, or a pharmaceutical composition, for use according to claim 23 or 24, wherein the compound is capable of reducing binding of LAG-3 to a MHC class II molecule. 26.) A compound, or a pharmaceutical composition, for use according to any of claims 23 to 25, wherein the compound is capable of enhancing a T cell response in a subject. 27.) A compound, or a pharmaceutical composition, for use according to any of claims 23 to 26, wherein the compound is capable of stimulating an immune response in a subject. 28.) A compound according to any of claims 1 to 21, or a pharmaceutical composition according to claim 22, for use in the prevention, treatment or amelioration of a cancer in a subject. 29.) A compound, or a pharmaceutical composition, for use according to claim 28, wherein the cancer is a solid tumor cancer, or a haematological cancer, or a metastatic lesion thereof. 30.) A compound, or a pharmaceutical composition, for use according to claim 29, wherein the solid tumor cancer is a sarcoma or a carcinoma.31.) A compound, or a pharmaceutical composition, for use according to any of claims 28 to 30, wherein the cancer is a lung (e.g., a non-small cell lung cancer (NSCLC) (e.g., a NSCLC with squamous and / or non-squamous histology) or small cell lung cancer), breast (e.g., a breast cancer that does not express one, two or all of estrogen receptor, progesterone receptor, or Her2 / neu, e.g., a triple negative breast cancer), renal, liver, prostate, cervical, bladder, lymphoid, gastrointestinal, gastric, colorectal, cancer of the small intestine, cancer of the oesophagus, genital, genitourinary tract (e.g., renal, urothelial, bladder cells), pharynx, CNS (e.g., brain, neural or glial cell), kidney (renal cell carcinoma (RCC), e.g., clear renal cell carcinoma (ccRCC) or metastatic renal cell carcinoma (MRCC)), skin (e.g., melanoma - e.g., stage II-IV melanoma, or HLA-A2 positive-melanoma), head and neck (e.g., head and neck squamous cell carcinoma (HNSCC)), or pancreatic cancer. 32.) A compound for use according to claim 29, wherein the hematological cancer is a leukemia (e.g., a myeloid leukemia, lymphoid leukemia, or chronic lymphocytic leukemia (CLL)), lymphoma (e.g., Hodgkin’s lymphoma (HL), non-Hodgkin’s lymphoma (NHL), Diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma, or mantle cell lymphoma (MCL)), or myeloma (e.g., multiple myeloma). 33.) A compound according to any of claims 1 to 21, or a pharmaceutical composition according to claim 22, for use in the prevention, treatment or amelioration of an infectious disease in a subject. 34.) A compound, or a pharmaceutical composition, for use according to claim 33, wherein the infectious disease is caused by any of the following viruses: hepatitis virus (A, B, or C), influenza virus (A, B, or C), HIV, herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, CMV, Epstein Barr virus), adenovirus, coronavirus, flavivirus, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus. 35.) A compound, or a pharmaceutical composition, for use according to claim 33, wherein the infectious disease is caused by any of the following bacteria: syphilis, chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme disease bacteria (Borrelia species).36.) A compound, or a pharmaceutical composition, for use according to claim 33, wherein the infectious disease is caused by any of the following fungi: Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum, or by any of the following parasites: Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis. 37.) A compound, or a pharmaceutical composition, for use according to any of claims 28 to 36, wherein the compound is capable of binding to LAG-3. 38.) A compound, or a pharmaceutical composition, for use according to any of claims 28 to 37, wherein the compound is capable of reducing binding of LAG-3 to a MHC class II molecule. 39.) A compound, or a pharmaceutical composition, for use according to any of claims 28 to 38, wherein the compound is capable of enhancing a T cell response in a subject. 40.) A compound, or a pharmaceutical composition, for use according to any of claims 28 to 39, wherein the compound is capable of stimulating an immune response in a subject. 41.) A method of treating or preventing a disease in a subject, comprising administering to a subject in need thereof a compound according to any one of claims 1 to 21, or a pharmaceutical composition according to claim 22. 42.) A method of stimulating an immune response in a subject, comprising administering to a subject in need thereof a compound according to any one of claims 1 to 21, or a pharmaceutical composition according to claim 22. 43.) A method of treating a cancer, comprising administering to a subject in need thereof a compound according to any one of claims 1 to 21, or a pharmaceutical composition according to claim 22. 44.) A method according to claim 43, wherein the cancer is a solid tumor cancer, or a hematological cancer, or a metastatic lesion thereof.45.) A method according to claim 44, wherein the solid tumor cancer is a sarcoma or a carcinoma. 46.) A method according to claim any of claims 43 to 45, wherein the cancer is a lung (e.g., a non-small cell lung cancer (NSCLC) (e.g., a NSCLC with squamous and / or non-squamous histology) or small cell lung cancer), breast (e.g., a breast cancer that does not express one, two or all of estrogen receptor, progesterone receptor, or Her2 / neu, e.g., a triple negative breast cancer), renal, liver, prostate, cervical, bladder, lymphoid, gastrointestinal, gastric, colorectal, cancer of the small intestine, cancer of the oesophagus, genital, genitourinary tract (e.g., renal, urothelial, bladder cells), pharynx, CNS (e.g., brain, neural or glial cell), kidney (renal cell carcinoma (RCC), e.g., clear renal cell carcinoma (ccRCC) or metastatic renal cell carcinoma (MRCC)), skin (e.g., melanoma - e.g., stage II-IV melanoma, or HLA-A2 positive-melanoma), head and neck (e.g., head and neck squamous cell carcinoma (HNSCC)), or pancreatic cancer. 47.) A method according to claim 44, wherein the hematological cancer is a leukemia (e.g., a myeloid leukemia, lymphoid leukemia, or chronic lymphocytic leukemia (CLL)), lymphoma (e.g., Hodgkin’s lymphoma (HL), non-Hodgkin’s lymphoma (NHL), Diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma, or mantle cell lymphoma (MCL)), or myeloma (e.g., multiple myeloma). 48.) A method of treating an infectious disease, comprising administering to a subject in need thereof a compound according to any one of claims 1 to 21, or a pharmaceutical composition according to claim 22. 49.) A method according to claim 48, wherein the infectious disease is caused by any of the following viruses: hepatitis virus (A, B, or C), influenza virus (A, B, or C), HIV, herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, CMV, Epstein Barr virus), adenovirus, coronavirus, flavivirus, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus. 50.) A method according to claim 48, wherein the infectious disease is caused by any of the following bacteria: syphilis, chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia,pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme disease bacteria (Borrelia species). 51.) A method according to claim 48, wherein the infectious disease is caused by any of the following fungi: Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum, or by any of the following parasites: Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis. 52.) A method according to any of claims 41 to 51, wherein the compound or composition is administered in a therapeutically effective amount. 53.) A method according to any of claims 41 to 52, wherein the treatment is affected or facilitated by the compound binding to human Lymphocyte Activation Gene-3 (LAG-3). 54.) A method according to any of claims 41 to 53, wherein the treatment is affected or facilitated by reducing binding of LAG-3 to a major histocompatibility (MHC) class II molecule. 55.) A method according to any of claims 41 to 54, wherein the treatment is affected or facilitated by enhancing a T cell response.
Citation Information
Patent Citations
Preparation method and application of five prenylated flavonoids
CN111747920A
Cytochalasin derived from phenylalanine and preparation method and application thereof
CN111808015A
Small molecule compound and application thereof as LAG3 protein inhibitor
CN114869877A
FR2070142A1
Phenylacetamido- pyrazole derivatives and their use as antitumor agents
WO2002048114A1
